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Abstract 
 
Cancer is a significant burden of disease worldwide. Amongst women, breast cancer is the 
most common cancer and the primary cause of death of women followed by heart diseases. 
With increasing breast cancer cases and technological improvements, large volumes of data 
related to breast cancer are collected every year around the globe. This historical data is a vast 
source of knowledge, and when extracted, this knowledge could be used in making decisions 
in the future. Descriptive analytics uncovers hidden patterns and trends and provides insights 
into the past to answer “What has happened?”. Predictive analytics uses different modeling 
techniques on historical data to predict future medical outcomes and answer “What could 
happen?”. 
Cancer care institutions and registries have collected large volumes of cancer data in 
various formats. Unfortunately, these repositories are not easily accessible, and the stored 
formats are difficult to analyze. The National Cancer Institute’s Surveillance, Epidemiology, 
and End Results (SEER) Program is a premier source for cancer statistics in the United States. 
Although the data is accessible, it lacks consistency; generating reports from such data is a 
labour-intensive process. An end-to-end process is proposed through which such data can be 
cleansed, integrated and presented in the form of interactive dashboards with drill-down and 
drill-through reporting capabilities. This provides a comprehensive view of over forty years of 
data consisting of over one million records with provisions to slice this data along several 
dimensions. The underlying patterns and trends could be utilized in improving treatment plans, 
data-driven resource allocation, and better patient care. The dashboard would be extensible, 
scalable, and update in real-time with new data.
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Additionally, developing a breast cancer predictive model that predicts survival months 
for diagnosed patients is proposed. The cleansed and pre-processed data from the analysis is 
used for creating data subsets, which in turn, trains the predictive model. The outcomes of 
different modeling techniques along with assessing the impacts of retraining the predictive 
model are observed in the experimentations conducted for this research. 
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1. Introduction 
 
 
Cancer is generally referred to as a large group of diseases that can affect any part of the human 
body. It is the uncontrolled growth of cells, which can invade one site or spreads to many sites 
within the body [1]. A constant increase in the number of cancer cases has been reported over 
the past decade globally. According to the American Cancer Society, there are over 1.6 million 
new cases, and over half a million cancer-related deaths were estimated to have been reported 
in the United States in 2016 alone [2]. Hence it is of no surprise that cancer is the second most 
leading cause of deaths in the United States. Cancer is a leading cause of deaths in Canada as 
well, accounting for 30% of all deaths according to the Canadian Cancer Society [3].  
There exist more than 100 types of cancer with different symptoms and treatment. 
Breast cancer is one of the most common cancer among women. However, due to technological 
advancements and increasing cancer-related research, many new early detection methods and 
treatments have been developed which have helped to decrease cancer-related deaths [4]. 
However, cancer in general and breast cancer, in particular, is still a significant cause of 
concern [5]. Breast cancer accounted for about 25% of all the new cancer cases among women 
in Canada in 2017, with an estimated total count over 26,000 for the year [3]. The numbers are 
on the rise globally, for both incidence and mortality due to breast cancer. 
“Breast cancer starts when cells in the breast begin to grow out of control. These cells 
usually form a tumor that can often be seen on an x-ray or felt as a lump” [6]. Breast cancer is 
most common in women, but it is also possible in men. The tumor is considered malignant if 
the cancer cells multiply and start affecting the surrounding cells or metastasize to other parts 
of the body such as the liver, lung, bone or brain. The tumor is benign or non-malignant when 
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there are abnormal growths, but do not invade other cells outside of the breast. Although non-
malignant tumors are considered not life-threatening, some benign breast tumors can increase 
a woman's risk of getting a malignant tumor in breast [6]. 
Even though breast cancer research is clinical or biological [5], the data-driven research 
outcomes can be valuable and a significant step forward in cancer treatment. Dr. Robert Stein, 
UCL breast cancer consultant, states that the one-size-fits-all basis is the common practice in 
all areas of cancer treatment [7]. However, tools like IBM Watson for Oncology [8] and SAP’s 
Corporate Oncology Program for Employees (COPE) [9] help physicians provide better cancer 
care. SAP’s COPE is corporate oncology program run by SAP for its employees in Germany, 
U.S and Canada. The program offers treatment cost coverage of tumor analysis and helps 
physicians find safe and effective treatment for each patient. IBM Watson [8] for oncology is 
trained to design cancer treatments. Over time, Watson has performed very well at 
recommending a treatment plan for different types of cancer. The clinicians continue to add to 
the Watson cancer assessing repository [10]. By selecting treatment plan based on genetic 
changes and evidence by understanding the data points, Watson, COPE and other tools have 
brought a paradigm shift in cancer care in today’s world.  
With such new tools and research aid, breast cancer care can be improved further. 
Predicting survival of breast cancer patient can provide physicians help in developing the 
treatment plan specific to each patient. Different modeling techniques that can be used to 
develop such predictive model. One hypothesis here is that Ensemble modeling technique can 
be more accurate than other modeling techniques when designing the breast cancer predictive 
model. Ensemble modeling is the process of combining two or more modeling techniques and 
score the combined results by using voting or averaging techniques. 
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1.1 Background 
 
One of the most frequently asked questions by cancer patients post-diagnosis is the lifespan 
they are left with. To predict how long a cancer patient will live is a tough question for 
oncologists to answer. Oncologists answer to such questions are based on past records of cancer 
patients with similar prognosis or by consulting other physicians and researchers working on 
comparable cases. Although careful prognosis is vital, it is difficult to find accurate survival 
time of patients because survivability is based on many factors [11]. Also, these predictions 
may not be absolute as the past records are not entirely reliable and the prognosis from different 
oncologists are generally inconsistent [12].  
 
1.1.1 Common Breast Cancer Research Methods 
 
The common breast cancer research methods include experimental, observational and clinical 
trials. The experimental method involves new medication, treatment plan or new treatment aid 
introduced to a new set of people. The results of a new intervention are then compared with 
another set of people (control group) who are not exposed to the new intervention being tested. 
The control group and other group’s members are selected randomly by the researchers. 
Experimental research methods help in testing the new techniques and learning how cancer 
starts or metastasizes. The second common research method is observational, which involves 
observing a set of people in a natural environment to determine factors associated with a 
specific outcome [13]. As a result, observational studies can establish the association of the 
variables to the outcome. Another common breast cancer research method is clinical trials. 
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Clinical trials are medical experiments performed on humans. The development of new 
procedures and drugs are usually developed based on clinical trials [4, 14]. 
In this research, observational research methodology is used. The historical data 
records of cancer patients are used to understand the patterns, trends (data analysis) and factors 
involved in the disease outcomes (data mining) and predict the outcome for new patients 
(predictive analytics). The purpose of this research is twofold: to develop a breast cancer 
dashboard and build a predictive model by utilizing the relationship between a set of 
independent variables and the survival months. 
1.1.2 Medical Prognosis and Survival Analysis 
 
Predicting the outcome of a disease is one of the most challenging tasks for researchers [5]. In 
cancer treatment survival is considered as the most important outcome [15]. “Survival analysis 
is a study of time between entry into observation and a subsequent event” [16]. In today’s 
world, scientists use survival analysis for not just commencement time of disease but also for 
the time before the stock market crash, time until weather changes or equipment failure, the 
time before natural calamities like flood, and earthquake [16]. For cancer, the essential event 
of interest is “death”. Other events include relapse of disease, recovery from disease or death. 
Survival analysis tools are also used for leukemia patient readmission time, time for an average 
person to develop a heart disease, the time before death for elderly population, and so on [17]. 
In medical prognosis “Survival analysis” is referred to a field which uses different 
methods and techniques on collected historical data, to predict the patient’s survival from a 
disease over a specific period of time [5]. With Electronic Medical Records (EMR) systems 
development, storing patient’s history, test results, diagnoses and other relevant facts has 
become easy and manageable. Moreover, such open source data source acts a tremendous 
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resource for researchers who want to develop survivability prediction models. Data analysis 
and knowledge discovery research techniques are used by researchers to predict the outcome 
of disease by identifying the patterns and relationship between different variables of historical 
data [5]. 
1.1.3 Knowledge Data Discovery and Data Mining 
 
Historical data from cancer patients’ medical records are a powerful source of information. It 
helps oncologists and researchers find the grounds for inter-relationships of present to 
historical cases [18]. Using historical data to predict outcomes in breast cancer could be dated 
back to 1992 where neural network analysis was used to predict the recurrence of breast cancer 
[19]. However, with no specific global standard to record the patient data, a vast inconsistency 
is often observed across the data available globally. Despite this inconsistency, these records 
remain invaluable medical literature.   
Knowledge Data Discovery (KDD) is a significant process of extracting knowledge 
from raw data. KDD is defined as a step-by-step process of understanding the realm, 
preparation of data, followed by the collection and formulation of knowledge from extracted 
patterns. The ‘‘post-processing of the knowledge’’ then can be applied to capture the 
knowledge from a large amount of recorded data [20]. In KDD, data mining is the step of 
collecting and formulating knowledge from data using different pattern extraction methods. 
The knowledge discovery process is an essential part of medical data mining [21].  
Data mining has influenced many fields such as medicine, media, astronomy, business, 
marketing, investment, manufacturing, and telecommunications. In today’s digital world, large 
volumes of data are produced every day, and manual data analysis is an impractical approach. 
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Thus an automated data analysis is the need of the hour. Data mining is the attempt to address 
a problem of the digital era, i.e. data overload [22]. Data mining uses different algorithms to 
extract useful patterns from data [23] and then use the patterns to build predictive models. 
There are two major data mining tasks, grouped as descriptive data mining and predictive data 
mining. The descriptive data mining includes association, clustering and summarization tasks. 
On the other hand, predictive data mining tasks include classification, prediction, and 
time-series analysis tasks [24]. Descriptive data mining tasks describe the significant  
properties of the actual data and predictive data mining tasks aim to do predictions based on 
existing data [25]. In this research, descriptive and predictive data mining tasks are used. 
 
1.1.4 Data Visualization 
 
A powerful option to make complex data usable and relevant is through data visualization. The 
goal of interactive data visualization is to display data in forms of visuals to help the user 
understand the data quickly, identify the areas of improvement and take decisions accurately 
based on historical events or data [26]. On a broader scale, there are two goals of data 
visualization – explanatory i.e. to explore data to solve a particular problem, or exploratory, 
i.e. to explore large sets of data for enhancing understanding of data and finding crucial missing 
information. Converting structured data into meaningful charts and graphical depictions enable 
the users to gain insights into all the captured data [27]. As the healthcare sector is rapidly 
moving towards data analytics and has started relying on digital information to improve health 
care and reduce the costs, data analysis and visualization of data has become a core component. 
Many health organizations also have online visualization tools available for public to explore 
the trends of incidence, mortality, demographics and other statistics. Institute of Health Metrics 
7 
 
and Evaluation’s “GBD (Global Burden Disease) Compare” is an interactive analytics and 
visualization tool available online [28]. The tools allow users to visualize and compare disease 
causes and risks in the form of treemaps, maps, diagrams, charts within the region (inter-
country or intra-country) or worldwide [28]. There are some online visualization tools and 
dashboards available for cancer data also. The National Program of Cancer Registries (NPCR) 
has the United States Cancer Data Visualization online tool [29] available which fetches data 
from National Cancer Institute (NCI) and Centres for Disease Control and Prevention’s CDC 
for all cancer types for the year 2010 - 2014. The visualization tools have U.S Cancer 
demographics represented graphically by cancer incidence rate, mortality rate and type of 
cancer. World Health Organization’s Global Cancer Observatory (GCO) is a web-based 
platform which provides global cancer statistics [30].    
 
1.1.5 Past Research 
 
Many former researchers have established the capacity of data mining by the medium of 
application to medical records [18]. For instance, Agrawal et al.’s Lung Cancer Outcome 
Calculator [5] is a survival prediction model for lung cancer patients using different data 
mining techniques and SEER data [31]. It can predict survival of lung cancer patients from 6 
months, 9 months, 1 year, 2 years and 5 years of diagnosis [5]. Zorluoglu et al. used Wisconsin 
Diagnostic Breast Cancer Database (WDBC) for similar work to predict whether a breast 
cancer tumor is malignant or benign [32]. Several other prognostic applications, using different 
tools and algorithms, also exist that can predict breast cancer survivability, for example, 
Adjuvant [33], PREDICT [34]. 
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1.2 Problem Statement 
 
Cancer care institutions and registries have collected large volumes of cancer data in various 
formats. Unfortunately, these repositories are not easily accessible, and the stored formats are 
difficult to analyze. The National Cancer Institute’s SEER Program is one of the organizations 
which maintains cancer statistics of the US population. Though the data is accessible, it lacks 
consistency and generating reports from such data is a labour intensive process.  
An end-to-end process is proposed through which this data is cleansed, integrated and 
presented in the form of interactive dashboards with drill-down and drill-through reporting 
capabilities. This provides a coherent view of the data and allows users to observe hidden 
patterns and trends which could be utilized towards improving treatment plans, data-driven 
resource allocation and better patient care. The top-level dashboard presents the main KPIs and 
is supported by a sequence of visualizations to convey information which can be sliced and 
diced along several dimensions. This real-time dashboard can be updated as soon as new data 
is uploaded to the database. 
Further by using the pre-processed and cleansed data, a breast cancer predictive model 
is proposed that predicts survival months of a breast cancer patient from the time of diagnosis. 
The predictive model is trained, tested and validated with different subsets. The predictor’s 
selection is based on main KPIs identified by analysis along with an expert’s opinion from a 
total of 134 variables available in SEER. Different data mining is used, and the predictive 
models will be designed based on data mining technique which performs best amongst all, 
along with the ensemble of selected techniques. 
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1.3  Motivation of the Research 
“Time is shortening. But every day that I challenge this cancer and survive is victory for me” – Ingrid 
Bergman (Cancer patient) 
 
The traditional cancer survival prediction methods such as research on past experiences using 
spreadsheets require an unacceptably large amount of time and effort to study the data. The 
classic ways of identifying survival time of cancer patients include a comparison study between 
the patient’s health situation and symptoms with previously recorded cancer patient’s medical 
records, statistical computation of survival rates based on historical records, or consulting 
another breast cancer expert.  
“Cancer prognosis is the doctor's best estimate of how cancer will affect person” [3]. 
 
Many factors that can affect a person's prognosis. Survival statistics is one of the 
methodologies that physicians use to develop a prognosis for a person with cancer. 
Researchers, when developing a prognosis, often look at studies that measure survival for one 
specific cancer type, stage or risk group. The survival rate is the percentage of people with 
cancer who are alive at some point in time (i.e. 1, 3, 5 or 10 years) after their diagnosis [3]. 
Survival prediction is the process of finding the time left for a patient to live. It is generally 
associated with diseases, which have high mortality rate such as cancer. Survival prediction is 
part of physician’s prognostic investigation, where a result takes the form of a numerical 
percentage of survival over a period that depends on a factor such as tumor size, time after 
diagnosis and stage of cancer [18]. Table 1 shows global survivability rates of breast cancer 
for the year 2016.  
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Time since Diagnosis Survival Rate 
5-year 89% 
10-year 83% 
15-year 78% 
 
Table 1. Breast Cancer Survival Statistics [2] 
 
 
All cancer types have high mortality rates [35] and cancer patients are always frenzied 
to know how much time they are left with. Despite many treatment options available for cancer 
patients, there is no assurance that the patient will be cured after treatment. Each patient 
responds to the treatment differently. Physicians estimate the prognosis of cancer by using 
statistics collected by researchers over many years. Various statistics are used to estimate 
cancer prognosis [36], most commonly: Cancer-specific survival, Relative survival, Overall 
survival and Disease-free survival. These statistical survival prediction methodologies are 
time-consuming and lack accuracy. By applying data mining techniques to breast cancer data, 
a breast cancer survival prediction model is built. Data mining techniques help rank and link 
cancer attributes to survival outcome [5]. The outcome of the breast cancer survival predictive 
model will help both physicians and patients to determine accurate survivability, serving as a 
reference for patients and provide them with a second opinion [18]. It can also assist physicians 
in decision-making to determine the best treatment for breast cancer patient. The modeling 
technique can predict outcome depending on patient-specific attributes instead of relying on 
personal experiences or time-consuming statistical evaluation. The combination of breast 
cancer effects across the different age range, the promising results and benefits of data-driven 
research in healthcare, and the desire to contribute towards improving healthcare and treatment 
of breast cancer have together motivated this research. 
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1.4  Research Methodology 
 
The main steps involved in this research are:  
 Literature review 
 Determining relevant data source 
 Consultation with medical personnel/oncologist to shortlist the relevant variables 
 Design data analysis dashboard 
 Determine relevant tools and modeling techniques 
 Develop a predictive model 
 Training, testing and validation of the predictive model 
 
1.5  Contributions 
 
This research has two primary contributions. The first contribution focuses on data 
visualization for breast cancer data of over 40 years. This is achieved by developing a 
dashboard built from breast cancer patients’ data to uncover hidden patterns as well as provide 
easy-to-understand metrics for users of all backgrounds. The dashboard includes breast cancer 
data for patient population demographics, patient volumes, diagnosis and treatment.  
The second contribution focuses on building a predictive model to predict breast cancer 
patient survivability. This model is built from the preprocessed data extracted from the SEER 
database. The model could be used by doctors to determine their predicted survival time 
ranging in months for their patients diagnosed with breast cancer. The model is trained with 
the existing data and processes the given breast cancer-related attributes and predict survival 
months [18]. This research will contribute towards the healthcare field in following ways: 
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1. Increase accuracy of the diagnoses: Predictive algorithms help physicians input the 
patient’s clinical symptoms and get more accurate diagnosis thereby assisting their 
judgements [37]. The treatment plan of patients can then be enriched with predictive 
analytics results such as survival months. 
 
2. Provide physicians with answers they are seeking for individual patients: There are 
possibilities where a treatment plan works best for a set of patients, but may or may not 
work for another individual patient. Predictive analytics can help physicians plan the 
treatment specific to the patient. The breast cancer treatment plan can include a 
combination of different treatments such as surgery, radiation therapy, chemotherapy, 
hormonal therapy and targeted therapies. An ideal treatment plan should work against all 
things inside the cells that caused cancer to develop, grow, and possibly spread to other 
parts of the body [38]. 
 
3. Increase the patients’ understanding and participation: The outcomes of predictive 
analytics like survivability and possible health risk indicators can help the patients’ 
educate themselves about their disease. An educated patient can take more responsibility 
of their treatment plan. The patients can then equally participate with their physicians to 
help make decisions on their treatment plan. 
 
4. Analyze massive healthcare data: In current scenarios, the massive amount of data 
generated by the healthcare industry is digitized for ease. It is a tedious work to make 
sense from such massive digital data. The analysis of healthcare data will help by 
providing actionable insights to both physicians and healthcare industries regarding their 
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planning, administration and assessment [37]. It thereby augments the decision-making 
ability of the administration, by evaluating the critical opportunities, such as quality care 
improvement or patient injury prevention, and allocating resources to the fundamental 
processes [39]. 
 
 
1.6  Organization of Thesis 
 
This thesis consists of five chapters. In this chapter, the background, problem statement, the 
motivation and contributions of this research has been provided. In Chapter 2, the related work, 
challenges and different research approaches are discussed. Chapter 3, extensively discusses 
the implementation steps involved in developing the breast cancer dashboard and the predictive 
model. Also, data mining and modeling techniques are formally introduced in this chapter. 
Chapter 4, provides experimentation and analysis of results. Chapter 5 provides the conclusion 
and the future directions to extend the work done in this research. 
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2. Literature Review 
 
To better understand the research questions raised and addressed in the problem statement, an 
extensive literature review is conducted. For this purposes, traditional/narrative literature 
review methodology is used. It involves critiquing and reviewing existing work and deduce a 
conclusion about the research questions raised. This review type comes handy in collecting a 
volume of related work in a specific research area and then summarize it by highlighting the 
current techniques and approaches used. By finding gaps or disparity in the literature, 
researchers can determine or define a new research approach or hypotheses. 
 
This process is utilized to understand the nuances of the approaches used in the 
literature specifically concerning two areas – data analysis and visualization of existing cancer 
data, and various predictive modeling techniques to determine the survivability of cancer 
patients. In this chapter, the observations in the two corresponding sections are presented.  
 
2.1 Cancer Data Analysis and Visualization 
 
Over the past few years, several studies have been conducted focusing on the analysis of data 
related to multiple types of diseases including breast cancer [28, 30, 40, 41]. More recently, 
several health organizations have developed online analytics and visualization tools for cancer 
and other diseases from their data repositories. Some of these tools available are discussed in 
the following sections: 
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2.1.1 Global Burden of Disease Compare 
 
 
Figure 1. Screenshot of GBD Compare Breast Cancer Incidence Visualization [28] 
 
 
The Institute of Health Metrics and Evaluation (IHME) [42] at the University of Washington 
measures, compares and evaluates strategies for various health issues, diseases, injuries and 
risk factors, around the globe. IHME’s tool, GBD [28] evaluates global health challenges and 
risk factors so that health systems can be aligned with the disease trends. The tool analyzes 
data from 1990-2016 and provides a comparison of the effects of different diseases on a set of 
population. The policymakers can thus make more informed decisions with respect to the 
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allocation of resources for better health care. The data related to premature deaths, disabilities, 
and injury is collected from over 130 countries and can be visualized along several dimensions 
including demographics, mortality, disease causes and risk factors [28]. The visualization is 
available in different formats such as map, treemap, line chart, patterns bar chart, pyramid 
chart, arrow chart and heat map. The dashboard can be drilled down to specific countries and 
states. The tool has three main tabs- single (single chart type), explore (map and one additional 
chart) and compare (two of the same chart by year, age, sex, cause of disease, risk and location). 
Figure 1 is a screenshot of line graph visualization from ‘compare by cause’ tab where 
the cause is selected as breast cancer. The colour-coded lines show breast cancer rate and trend 
for selected countries. The same website also provides links to other visualization projects such 
as Mortality, Cause of Death (COD), Epidemiological (Epi), and Financing Global Health. 
[43]. 
2.1.2 U.S. Cancer Statistics Data Visualizations Tool 
 
The Centers for Disease Control and Prevention (CDC) [44] and the National Cancer Institute 
(NCI) [45] collects cancer data from hospitals, physicians, clinics and health labs all over the 
U.S. and have made this data available through a visualization tool [40]. CDC recommends 
professionals like planners, policymakers, health advisors, researchers, and journalists to use 
this information to view and report cancer statistics [44]. The dashboard has multiple tabs and 
dropdowns for cancer types, historical trends, incidence, mortality rate, gender, age and 
demographics. While the data includes cases registered in the year 2010-2014, nation-wide 
changes in rates are available for the period 2006-2014. 
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Figure 2. Screenshot of CDC Visualization tool [40] 
 
Additional functionality includes geographical distribution displayed on an interactive map 
together with comparative numbers for all states [40]. Figure 2 is a screenshot of CDC 
visualization from demographics tab showing the rate of new cancer by sex, age group, 
race/ethnicity for all types of cancer in the United States (2015). 
 
2.1.3 Global Cancer Observatory 
 
World Health Organization’s (WHO) [46] GCO [30] is a web-based visualization tool for 
global cancer statistics. The data presented is gathered from different projects of International 
Agency for Research on Cancer (IARC) Section of Cancer Surveillance (CSU) [47] 
including GLOBOCAN [48], Cancer Incidence in Five Continents (CI5) [49], International 
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Incidence of Childhood Cancer (IICC) [50], and Cancer Survival in Africa, Asia, the Caribbean 
and Central America [51]. The dashboard has four main tabs – Cancer Today, Cancer over 
Time, Cancer Tomorrow and Cancer Causes. The ‘Cancer Today’ tab presents incidence, 
mortality, and types of cancer estimates for 184 countries, broken down by age group and 
gender. The ‘Cancer over Time’ tab shows trends of cancer incidence and mortality for the last 
50 years for 40 countries. The ‘Cancer Tomorrow’ tab provides visualization of cancer 
prediction up to the year 2035 by country and cancer type. Finally, ‘Cancer Causes’ tab 
highlights the causes of cancer, and the vital contributing risk factors [30]. Figure 3 is a 
screenshot of GCO visualization from ‘Cancer Today’ tab displaying estimated top 10 cancer 
incidence (cases) in the year 2018. 
 
 
Figure 3. Screenshot of GCO Visualization [30] 
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2.1.4 Genomic Data Commons DAVE Tools  
 
The National Cancer Institute’s [45] Genomic Data Commons (GDC) [52] provides access to 
standardized clinical and genomic data. GDC also includes data from, The Cancer Genome 
Atlas (TCGA) [53] and Therapeutically Applicable Research to Generate Effective Therapies 
(TARGET) [54]. The GDC Data Analysis, Visualization, and Exploration (GDC DAVE) Tools 
[41] provides cancer supporting gene and variant level analysis of GDC data. These tools 
provide researchers’ ability to visualize gene data with high impact mutations, most frequently 
mutated genes, survival analysis of different cases, and graphical visualization of cancer gene 
mutations. The data from each analysis can be visualized in bar charts, graph plots, trend lines 
and tabular format, along with download functionality. Figure 4 is a screenshot from GDC 
DAVE Tool visualization, showing a distribution of most frequently mutated genes. This tool 
can be accessed by using the GDC Data Portal. 
 
 
Figure 4. Screenshot of GDC DAVE Tool Visualization [41] 
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GDC provides data sharing, data submission across different cancer genomic studies 
and research thereby supports the development of precision medicine for cancer. A secure 
GDC API is also developed to provide batch data submissions [52]. 
 
2.1.5 Summary of Cancer Data Analysis and Visualization 
The tools discussed above are new and recently available platforms to analyze and visualize 
cancer data. While each of them is simple and easy to use, they are all tied to the databases 
which are not publically available. With no scope of adding a custom database at the backend, 
it leaves these tools as standalone projects that cannot be integrated into other projects or tools. 
More importantly, these tools haven’t been available for public use for long which diminishes 
the scope for a comprehensive evaluation or comparison among them. 
Since all these tools are deployed over the web, there are no distributions available to 
use them offline or on desktop modes. The wide variety of options to visualize data, prove 
handy to understand the trends better and inspires the researchers to design a similar tool. It 
serves as a motivation to design a flexible, scalable, easy to integrate platform, with 
visualization features comparable to these tools that could accommodate varying databases. 
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2.2 Predicting Breast Cancer Survival using Data Modeling Techniques 
 
Predicting the outcome of a disease is one of the most challenging tasks for researchers and 
medical personnel. In cancer treatment, survival is considered the most critical outcome [15]. 
Cancer survival prediction using data mining on historical records is possible. The existing 
predictive models have used data mining techniques such as artificial neural networks, decision 
trees and statistical methods to predict cancer survival. The different approaches used for 
cancer survival prediction are grouped into three categories – (i) comparison of different 
modeling techniques [11, 55, 57, 59, 60, 61, 62] to identify the most accurate prediction model, 
(ii) hybrid prediction model [65, 66] and (iii) ensemble of different modeling techniques [5, 
18, 32, 68].  
 
2.2.1 Comparison of different Modeling Techniques  
 In 2005, Delen et al. [55] developed breast cancer prediction model and compared different 
modeling techniques. Two data mining techniques, i.e. artificial neural networks, decision trees 
(C5) and one statistical technique, logistic regression were compared. The study used the SEER 
public-use database [31] for the year 1973-2000. The software packages used in the research 
for exploring data were MS Access database, SPSS statistical analysis tool, STATISTICA data 
miner and Clementine data mining toolkit. The data source was pre-processed, and the final 
dataset consisted of 202,932 records. The modification and removing of records were 
completed to predict survivability exclusive to breast cancer. Data cleansing and preparation 
strategies followed are as described below: 
 The records in which the patient didn’t survive for sixty months post-diagnosis were 
removed. 
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 The records with “Cause of Death” other than breast cancer were removed. 
 The records of those that were not followed up for sixty months were removed. 
 The records with missing values were removed. 
 The records with unusual “Tumor Size” variable values were also eliminated. 
Only 17 out of 72 variables were selected; these included 16 predictor variables and 1 
dependent variable. Some of the key variables used were: race, age, grade, marital status, 
primary site code, histology, behaviour, extension of disease, lymph node involvement, 
radiation, stage of cancer and tumor size. The binary ‘dependent variable’ was assigned values 
of 0 and 1, where 0 denoted ‘did not survive’ and 1 denoted ‘survived’. The comparative 
performance of three data mining methods was evaluated by accuracy, sensitivity, specificity 
and k-fold cross-validation. The results showed that decision tree (C5) was the best predictor 
with the highest accuracy of 93%; followed by artificial neural networks with an accuracy of 
91.2%, and logistic regression with an accuracy of 89.2% [55]. Some of the shortcomings of 
this study are: 
1) The pre-classification method used in the study for determining the records of 
‘died/not survived’ category was incorrect.  
2) The study is based on the assumption that all patients died due to breast cancer only, 
which is not always the case [56].  
3) The study did not use Vital Status Recode (VSR) and Cause of Death variables. 
VSR marks whether the patient is dead or alive as of study cut-off date and Cause 
of Death provides the reason of cause of death of the patient. These two variables 
have been shown as important variables for cancer survival prediction [57] and 
other related studies.  
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Several spin-offs of their work followed through the years, and the SEER public-use 
data was observed to be used as the primary data source for these studies. In 2006, Bellaachia 
and Guven [57] implemented data mining techniques on breast cancer data to enhance Delen 
et al.’s study. The study included two more variables in addition to the 17 variables selected 
by [55], i.e. Cause of Death and Vital Status Recode. A new dependent variable Survivability 
was derived using Survival Time Recode (STR) and VSR. For a 60-month threshold, the 
‘Survivability’ variable was calculated using the logic shown in Figure 5. 
 
Figure 5. Survivability calculation by Bellaachia and Guven [57] 
 
 
SEER public-use database [31] was used for the period 1973-2002. The study compares 
three data mining techniques: Naïve Bayes, back-propagated neural networks, and C4.5 
decision tree algorithm. WEKA [58] toolkit software package was used for developing the 
prediction model. Accuracy, precision, and recall performance measures were used to evaluate 
the data mining techniques. The experimentation ranked Naïve Bayes technique as best with 
84.5% accuracy, followed by artificial neural networks and C4.5 algorithms with 86.5% and 
86.7% accuracy, respectively. With respect to Delen et al.’s study, the variation in the accuracy 
of the two studies is due to different SEER datasets, pre-processing and data mining techniques 
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[57]. One limitation of this study, as stated by the authors, is the exclusion of records with 
missing data (Extent of Disease and Site Specific Surgery).  
Endo et al. [59] compared seven algorithms to predict breast cancer survival using the 
SEER public-use database [31] from the year 1992 to 1997. Logistic Regression model, 
Artificial Neural Network, Naïve Bayes, Bayes Net, Decision Trees with Naïve Bayes, 
Decision Trees (ID3), Decision Trees (J48) were used to develop the prediction models. 
Among these methods, the Logistic Regression model showed the highest accuracy with 
85±0.2%, Decision tree (J48) showed the highest sensitivity and ANN displayed the highest 
specificity. The study used accuracy to evaluate the model performance, but the authors also 
state that sensitivity is a comparatively better parameter for survival based prediction models. 
A study by Wang et al. [11] predicts 5-year breast cancer patient survivability by using 
two data mining techniques, i.e. Logistic Regression model and a Decision Tree model. The 
study is performed on the the SEER public-use database [31]  for the year 2010. The study 
concludes that the Logistic Regression model is better than the Decision Tree model [11]. The 
study uses the same data preparation method as used by [55]. The dataset used in both the 
studies are different. The incidence and mortality trends in the datasets used by both these 
studies are significantly different. This study concludes with higher accuracy than [55]. The 
former study shows 91.19% and 91.34% accuracy while the latter shows 85.8% and 86.0% 
accuracy of decision trees and logistic regression respectively.  
Few studies [60, 61, 62] as discussed next, have developed a breast cancer detection 
model which predicts whether the cancer is present or not. These studies have also used data 
mining techniques and performed a comparison of these techniques. 
Chaurasia and Pal [60] developed a diagnosis system for breast cancer detection. The 
model uses RepTree, RBF Network and Simple Logistic modeling techniques. The study uses 
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University Medical Centre Institute of Oncology, Ljubljana, Yugoslavia database. The 
extracted breast cancer data had 286 rows and 10 variables for each row. The results of the 
study state that Simple Logistic modeling technique has higher accuracy (74.47%) as compared 
to RepTree (71.32%) and RBF Network (73.77%). 
Senturck and Kara [61] performed a breast cancer diagnosis study using data mining 
on the UCI Machine Learning database from the University of Wisconsin Hospitals, Madison. 
The study aimed to analyze the performance of seven different algorithms. RapidMiner 5.0 
[63] tool was used for data mining and prediction. The study concluded that a Support Vector 
Machines algorithm is best for breast cancer diagnosis prediction with an accuracy of 96.0% 
[61]. The study predicts if the tumor is benign or malignant. The prediction model is trained 
with 699 cases only (records with missing information were removed).  
Chaurasia and Pal [62] developed a breast cancer detection model using WEKA [58] 
software for data mining. This study also used UCI Machine Learning database from the 
University of Wisconsin Hospitals, Madison. The study aims to compare the performance of 
three classification techniques: Sequential Minimal Optimization (SMO), IBK and BF Tree. 
The study concludes that SMO classification techniques have the highest prediction accuracy 
(96.2%) amongst all three techniques. This study is different from their earlier work [60] in 
which that Simple Logistic, RepTree and RBF Network modeling techniques were used. The 
databases used in both studies are from different demographics.  
2.2.2 Hybrid modeling for Predicting Breast Cancer Survival 
 
Hybrid modeling is an approach when two or more modeling techniques are combined, for 
example, clustering and classification techniques combined or clustering and association 
modeling techniques used together [64]. 
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In 2008, Khan et al. [65] investigated a hybrid scheme based on fuzzy decision trees as 
an alternative to breast cancer prognosis. The data source used for the study was the SEER 
public-use database [31] for the period 1973-2003. An essential aspect of the research was to 
use a hybrid modeling technique based on Fuzzy Decision trees. Data pre-processing method 
removed the records having missing data and included only records with a Cause of Death 
(COD). The final dataset of 162,500 records with 16 variables and a binary target variable (0 
denoted ‘did not survive’ and 1 denoted ‘survived’) was used for experimentation. The 
performance measure evaluation stated that hybrid fuzzy decision tree classification technique 
(accuracy 85%) is more powerful and fair than independently applied decision tree 
classification technique (accuracy 82%) [65]. The study is also based on an assumption similar 
to Delen et al. [55] that all patients died due to breast cancer only, which is not always the case. 
A 2012 survey states that external causes, heart failure, suicide and gastrointestinal diseases 
are other reasons for breast cancer patient death [56]. 
According to Choi et al. [66], a hybrid Bayesian model for predicting breast cancer 
prognosis can outperform other models. Three different model for cancer prognosis were 
examined: Bayesian Network (BN) model, Artificial Neural Network (ANN) model and hybrid 
BN model. The hybrid model developed was a combination of an ANN model and the BN 
model. The SEER public-use database [31] for the time period 1973-2003 was used to build 
the model with 294,275 records and 9 input variables. For a threshold of 60 months, the 
proposed hybrid BN model performed better than the Bayesian network [66]. The study states 
that the proposed hybrid BN model and the ANN models outperformed the BN model. The 
goal of this study was to explain the power of BN models over ANN models. However, the 
study results showed that the hybrid BN model’s performance was mainly due to ANN model 
instead of the BN model. The Area Under Curve (AUC) of ANN (0.930) difference from 
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Hybrid BN (0.935) is minimal (0.005) as compared to BN (0.813). Authors stated that the 
better performance of the hybrid BN was originated from ANN instead of BN.  
 
2.2.3 Ensemble Modeling Technique for Predicting Cancer Survival  
Ensemble modeling techniques are used to improve the performance of individual 
classification techniques such as decision trees, regression, neural networks, support vector 
machines and Bayesian networks. Ensembles combine predictions of multiple classification 
techniques to achieve better prediction accuracy [67]. Common ensemble techniques used are 
bagging, boosting, voting and stacking. Ensembles modeling techniques only combine 
classification techniques, unlike hybrid modeling technique which can combine classification 
and clustering, or clustering (example- K-Means and two-step clustering models) and 
association techniques (example- Apriori and Carma models). 
In 2010, Agrawal et al. [5] developed an online lung cancer outcome calculator, using 
data mining and predictive modeling. The research aimed at developing an accurate survival 
prediction model by using the SEER public-use database [31]. The study used 1998-2001 data 
for five-year prediction. Records earlier than 1998 were eliminated because some variables 
were added only after 1998. Few variables were modified and merged to form new variables 
for the study. Only records with “Cause of Death” as lung cancer were used. The WEKA [58] 
software tool was used to evaluate the data mining techniques used. An ensemble of the data 
mining algorithms- J48 Decision Tree, Alternating Decision Tree, Logit Boost, Random 
Subspace and the Random Forest was used in the study. The predictive model was built with 
64 variables, and the online calculator was built by using 13 of 64 variables. 
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Figure 6. Lung Cancer Outcome Calculator screenshot [5]  
 
The 13 variables were selected based on the predictive power1 by using a feature 
selection2 method. Some of the key variables used were: age, birthplace, cancer grade, farthest 
extension of tumor, lymph node involvement and total regional lymph nodes examined. 
Overall, the ensemble voting classification technique performed best with the highest 
                                                 
1 Predictive power: The predictive power of an attribute here refers to the ranking or inter relatability ability of 
that attribute with other attributes to form patterns [101]. 
2 Feature selection: It is used to identify the fields that are most important for a given analysis. 
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prediction accuracy (91.4%) and AUC (94%) [5]. Figure 6 shows a snapshot of the online lung 
cancer calculator result window. 
In 2014, GilTroy Paular Meren [18] developed a Breast Cancer Outcome-Survival 
Online Measurement (BOSOM) calculator. An online survival measurement calculator using 
data mining and predictive modeling on the SEER public-use database [31] (1973-2010). The 
study uses the framework and data mining techniques as Agrawal et al.’s ‘Online Lung Cancer 
Outcome Calculator’ to establish the prediction calculator. The time interval used for 
prediction includes 2 years, 4 years, 6 years, 8 years and 10 years. The study concluded with 
the average accuracies of the calculator and completed dataset as 88.27% and 91.71%, 
respectively. Figure 7 is a snapshot of the BOSOM calculator output screen. The classifiers 
used in this study are same as used in [5]. The calculator of this study is a replica of LCOC [5] 
using the same methodology for breast cancer survivability. 
 
Figure 7. BOSOM Calculator - Table for Predicted Survival [19] 
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Gokhan and Mustafa [32] used an ensemble of three data mining techniques to diagnose 
breast cancer. Clementine software was used for data mining on the Wisconsin Diagnostic 
Breast Cancer Database. Amongst Decision Trees, Support Vector Machines, Artificial Neural 
Network and an ensemble of all three, the ensemble model proved to be better than individual 
models. The dataset used in this study has 569 instances or records. The limited data used in 
this study was one of the major shortcomings of this study. The study only determines whether 
the case is malignant or benign.  
Lastly, in 2017, Huang et al. [68] compared Support Vector Machine (SVM) modeling 
technique with SVM ensemble technique for breast cancer prediction. The datasets used in the 
study are Wisconsin Diagnostic Breast Cancer Database, UCI machine learning database and 
ACM SIGKDD Cup 2008. WEKA [58] data mining software is used to construct SVM 
classifiers. It is concluded that for smaller datasets, SVM ensembles performed better than 
individual SVM classification technique. For large datasets, SVM ensembles using the 
boosting method performs better than the other classification techniques. The results are 
presented in Table 2 [68]. 
 
Dataset Modeling Technique Accuracy (%) 
Small-scale 
dataset 
Individual SVM GA+linear SVM 96.57% 
SVM Ensemble 
GA+RBF SVM (boosting) 98.28% 
GA+linear SVM (boosting/bagging) 96.57% 
Large-scale 
dataset 
SVM Ensemble 
Poly SVM (boosting) 99.51% 
GA+poly SVM (bagging) 99.50% 
RBF SVM (boosting) 99.52% 
 
Table 2. Accuracy Comparison of SVM and SVM Ensembles [68] 
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2.2.4 Summary of Breast Cancer Prediction using Data Modeling Techniques 
 
Table 3 summarizes the data modelling techniques used for cancer survivability prediction in 
literature. 
 
Type Author Year Dataset Technique 
Comparison 
of different 
modeling 
techniques 
Delen et al. 2005 SEER public-use 
database 
(1973 – 2000) 
Decision Tree (C5), 
Artificial Neural Network, 
Logistic regression 
Bellaachia and 
Guven 
2006 SEER public-use 
database (1973 – 
2000) 
Naïve Bayes, 
Back-propagated Neural 
Network, 
C4.5 Decision Tree  
Endo et al. 2008 SEER public-use 
database (1992 – 
1997) 
Logistic Regression, 
Artificial Neural Network, 
Naïve Bayes, 
Bayes Net, 
Decision Trees with naïve 
Bayes, 
Decision Trees (ID3), 
Decision Trees (J48) 
Wang et al. 2013 SEER public-use 
database (1973 – 
2007) 
Logistic Regression, 
Decision Tree (J48) 
Senturk and Kara 2014 UCI Machine 
Learning 
Repository 
Artificial Neural Network, 
Decision Trees, 
Logistic Regression, 
Support Vector Machines, 
Naïve Bayes, 
K-Nearest Neighborhood 
Chaurasia and Pal 2017 University 
Medical Centre 
Institute of 
Oncology, 
Ljubljana, 
Yugoslavia 
database 
RepTree, 
RBF Network, 
Simple Logistic 
2017 UCI Machine 
Learning 
Repository 
SequentialMinimalOptimizatio
n, 
IBK, 
BF Tree 
Hybrid Khan et al. 2008 SEER public-use 
database 
(1973 – 2003) 
Decision Trees, 
Fuzzy Decision Trees 
Choi et al. 2009 SEER public-use 
database 
(1973-2003) 
Artificial Neural Network, 
Logistic Regression, 
Bayesian Network 
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Ensemble Agrawal et al. 2010 SEER public-use 
database 
(1988-2001) 
J48 decision tree, 
Random forest, 
LogitBoost, 
Random subspace 
Alternating Decision Tree 
GilTroy Paular 
Meren 
2014 SEER public-use 
database 
(1973-2010) 
ZeroR, 
Random forest, 
LogitBoost, 
Random subspace, 
J48 Decision Tree, 
Alternating decision Tree 
Gokhan and 
Mustafa 
2015 Wisconsin 
Diagnostic Breast 
Cancer Database 
Decision Trees,  
Support Vector Machines, 
Artificial Neural Network 
Huang et al 2017 Wisconsin 
Diagnostic Breast 
Cancer Database, 
UCI machine 
learning database, 
ACM SIGKDD 
Cup 2008 
SVM, 
SVM ensemble 
 
Table 3. Data Modeling Techniques used in Cancer Survivability Prediction 
 
2.3 Summary 
 
In this chapter, an overview of research done on breast cancer survivability has been provided. 
The models presented in the literature are based on several data mining techniques and different 
datasets. Most of these works focus on comparing data mining techniques for building 
predictive models, and only a few have developed specific tools to predict the outcome 
(survival) based on the patient-specific input. Predicting survivability of breast cancer patients 
can greatly assist physicians in developing the treatment plan specific to each patient. In the 
next chapter, the methodology used for this research along with implementation steps are 
discussed. 
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3. Methodology  
 
As mentioned in Chapter 1, the two main contributions of this thesis are the prediction of breast 
cancer survivability and analysis of breast cancer data. This chapter breaks down the 
overarching contributions into the sets of smaller tasks and explains each of the tasks along 
with presenting the rationale behind finalizing the routes adopted and choices made to 
accomplish them. In precision, the chapter presents various approaches that could be used for 
predicting survivability and analyzing breast cancer data, the predictive model along with 
implementation details of the different modeling techniques used for developing the predictive 
model to predict survival months, and the dashboard to visualize 40 years of historical breast 
cancer data.  
 
3.1 Proposed Approach 
 
Figure 8. Methodology gives an overview of the method used for this research. It is primarily 
divided into five tasks: data extraction (from raw data), data analysis (including pre-
processing), data visualization, predictive modeling, and evaluation of the predictive model. 
3.1 Data Extraction 
The SEER database maintains cancer statistics for the US and monitors annual cancer 
incidence progression of various types of cancer. The breast cancer data occurring in different 
population subgroups is available for the period from 1973-2013. Among other variables, the 
data includes patient records, race/ethnicity, primary site, the first course of treatment, and 
follow-up vital status [69]. The “SEER limited-use” data is defined by demographics, treatment  
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Figure 8. Methodology 
 
(Icons copyright: SEER*Stat, Microsoft, tableau and IBM) 
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(e.g. surgery, radiation therapy), diagnosis (e.g. primary site, tumor size), and an outcome 
characteristic (e.g. survival time, cause of death), which makes SEER an excellent source for 
outcome analysis and prediction-based studies. The SEER dataset used for this research is a 
collection of data from 18 registries. SEER*stat statistical software [70] is used to extract raw 
data from the SEER database. This software allows viewing of patient record and production 
of different sessions such as Frequency, Rate, Survival, and Case Listing. After consultation 
with a radiation oncologist, 30 variables were selected (from a total of 134 variables available 
in SEER) to prepare the relevant dataset. The dataset is filtered to only include cases, which 
died due to cancer, i.e. ‘Dead’ and ‘N/A not first tumor’ are selected for the SEER cause-
specific death classification (the detailed definition of SEER variables are presented in 
Appendix B). 
 
3.2 Data Analysis  
Data analysis is the process of transforming raw data into usable form. Once the raw records 
are extracted, data preprocessing is performed to produce a relevant subset. The pre-processed 
data is imported into the SQL Server database [71], followed by analysis leading to building 
the dashboard and reports using Tableau. 
a) Data preprocessing 
The data preprocessing is done at two levels: 
 SEER-related preprocessing: Normalization of data, such as converting text values 
to numeric representation is performed as a part of preprocessing. SEER*stat software 
is used to accomplish this task. The derived data is cleansed for eliminating redundant 
content. Male breast cancer cases are also eliminated as a part of data cleansing. 
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 Problem-specific preprocessing: This includes selecting data records for a distinct 
time of significance and eliminating attributes which do not hold any considerable 
predictive power. One of the steps is the removal of records which represent deaths due 
to a reason other than breast cancer. 
b) Data Modeling 
The pre-processed data is imported into MS SQL Server to create a database consisting of 
relevant dimensions and measures. Tableau [72] is connected to the database, and the tables 
are joined to create a view, extending horizontally by adding columns of data, as needed. The 
data is further cleansed (such as by changing data types, renaming & resetting fields) and 
prepared for analysis. Calculated fields, formulas, grouping and sets are added via SQL 
queries. The data is sliced and diced by using filters and parameters. The dissected data is then 
visualized using workbook, dashboards, and stories. 
 
3.3 Data Visualization 
 
The dashboard and dynamic reports contained in them use views and tables created in the SQL 
Server database that help convert massive amounts of data into meaningful and actionable 
information. This is accomplished by building dashboards which contain visually appealing 
and interactive components including charts, graphs, tooltips, and drill-down/ drill-through 
reports.  
Dashboards provide interactive access to informative data and help understand the 
enormous data generated by every cancer incidence. In addition to tracking of KPIs, the reports 
also allow discovery of hidden patterns in the data. All of this, in turn, can improve the quality 
of cancer care. The policymakers, health professionals, advisors, and planners could use this 
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data to view and report breast cancer statistics which provide a better understanding of the 
incidence and mortality trends. Physicians can identify treatment options, wellness programs, 
and patient engagement. It can also empower patients to choose the right care through 
interactive visualization of treatment cost, quality and effectiveness.  
 
3.4 Predictive Modeling 
By using the pre-processed and cleansed data, a breast cancer predictive model has been 
designed to predict survival months of a breast cancer patient from the year of diagnosis. The 
predictive model has been trained, tested and validated with SEER data. The predictors 
shortlisting is based on main KPIs identified by the analysis. Seeking an expert’s opinion in 
choosing the relevant predictors from a total of 134 variables available in SEER is an inevitable 
process for this task. By using various data modeling techniques, the predictive model has been 
developed with modeling techniques of highest accuracy, along with their ensemble. There are 
three crucial steps in this stage: selection of predictors, selection of training and testing 
datasets, and developing the predictive model using the training dataset. 
 
3.5 Evaluation 
The predictive model has been evaluated on the testing dataset: 
a) By comparing the actual average survival month with predicted survival months.  
b) By calculating the performance metrics such as accuracy. 
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3.2 Breast Cancer Analysis and Visualization 
 
With increasing cases of cancer, the amount of data associated with cancer has also increased 
proportionally. Analyzing such huge datasets is difficult. Dashboards provide a visual 
mechanism to track KPIs and other metrics relevant to specific processes [73].  The purpose 
of the dashboard is to capture, process, and distribute information in an intelligible format to 
enable users to understand the data better [74]. This, in turn, can improve the quality of cancer 
care.  
For this research, a combined dataset of over 40-year historical breast cancer data has 
been used. The dataset, which holds data in the raw form, is analyzed and then set for 
visualization by means of interactive reports and dashboard. The dashboard helps uncover 
hidden patterns as well as provide easy-to-understand metrics for users of all backgrounds. The 
dashboard includes breast cancer data for patient population demographics, patient volumes, 
diagnosis and treatment. 
There are several data visualization tools available such as SSRS, Tableau, Power View 
and Qlik View, which can be used to build dashboards and visualize data. In this research, 
Tableau is chosen because of its versatility, flexible interface and other capabilities described 
in the following section. 
 
3.2.1 Tableau 
 
Tableau [75] is a commercially available tool, which allows building dashboards by 
transforming data into visually appealing and interactive visualizations. It can be connected to 
a variety of data sources such as Access, Excel, and data warehouse or web-based data [76]. It 
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is an easy-to-use tool for data analysis and building dashboards together with drill-down and 
drill-through reports. Such visualization can help users (physicians, researchers & patients) to 
find the right path forward. For example, physicians can identify treatment options, wellness 
programs, and patient engagement. It can even empower patients to choose the right care 
through interactive visualizations of treatment cost, quality and effectiveness [72].  
Tableau is a useful tool for organizations which have massive amounts of data (e.g. the 
healthcare industry) to be converted into meaningful and actionable information. Also, the 
reports generated by Tableau can be published to a shareable URL [77]. Tableau can extract 
useful information out of large data, which is otherwise difficult to examine manually. The 
advantages of using Tableau as a Business Intelligence (BI) tool in this research are: 
 Tableau can discover hidden patterns in the data. 
 Tableau is an easy to navigate tool with simple drag and drop features for creating 
dashboards. 
 Tableau can analyze millions of rows of data in seconds. 
 Gartner’s BI Magic Quadrant [78] report has ranked Tableau as a leader for four 
consecutive years [79]. 
 Tableau can link multiple data sources (such as databases, flat files, web services) for 
quick and accurate analysis. 
 Tableau can provide real-time dashboards.  
 Tableau provides an option of extracting data from the data source or have a live 
connection with the data source such as healthcare environments. 
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3.2.2 Accessing SEER Database and SEER*Stat 
 
The SEER Program [80] is a database of cancer statistics in the United States. SEER is 
supported by the Surveillance Research Program (SPR) [81] in the National Cancer Institute’s 
Division of Cancer Control and Population Sciences (DCCPS) [82]. The SEER database 
monitors the annual cancer incidence progression of each type of cancer.  
The SEER public-use data is available from the SEER web site on submitting a SEER 
limited-use data agreement form [31]. The data agreement form is available in Appendix A. 
The data can be accessed by two different options, SEER*Stat’s client-server mode or by 
downloading compressed files. The first method requires the download and installation of 
SEER*Stat software [70]  on the machine. It requires an internet connection to extract data 
from the SEER database. The variables selected by the user are transferred from the user’s 
machine to the SEER*Stat server to retrieve data as per the ad-hoc requests submitted. The 
second method requires the user to download compressed files of the data in two formats, i.e. 
binary and ASCII version of data. These files can then be accessed using the SEER*Stat 
software. 
 
3.2.3 Data Understanding, Preparation and Extraction 
 
The SEER*Stat statistical software version 8.3.5 is used to obtain breast cancer data. 
SEER*Stat software is associated with the SEER research data - available either directly from 
SEER’s server or a local file. For this research, the first method is used, i.e. extracted data 
using SEER*Stat software and SEER*Stat server. SEER*Stat software provides different 
types of sessions, designed to calculate specific statistics. The software helps to view a given 
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record of a cancer patient and can produce different sessions such as frequency, rate, survival, 
and case listing sessions. In this research, a case listing session is used to get data at the 
individual case or patient level. Case listing session also allows accessing the data in ASCII 
text format and generates a dictionary for each variable selected. 
 
 
Figure 9. Selecting Database in SEER*Stat 
 
The database selection could be made as shown in Figure 9. For this research database 
used is “Incidence-SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana 
Cases, Nov 2015 Sub (1973-2013 varying)”. This dataset is a collection of data from 18 
different SEER registries i.e. Atlanta, Connecticut, Detroit, Hawaii, Iowa, New Mexico, San 
Francisco-Oakland, Seattle-Puget Sound, Utah, Lost Angeles, San Jose-Monterey, Rural 
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Georgia, Alaska Native Tumor Registry, Greater California, Greater Georgia, Kentucky, 
Louisiana and New Jersey [45]. The selected dataset has data for all types of cancer and 134 
variables to use. 
The ‘Selection’ tab allows filtering the database by site and morphology, year of 
diagnosis and other factors to customize the data extraction with respect to the research. The 
filters used on the selected database are shown in Figure 10. Following are filters are applied: 
 Only known age cases in research database are included 
 Site and Morphology is selected as ‘Breast’ 
 Year of diagnosis is selected from 1973-2013 
 Only ‘Dead’ and ‘N/A not first tumor’ is selected for SEER cause-specific death 
classification. 
 
Figure 10. Filters used in SEER*Stat 
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Table 4. List of short-listed Variables 
 
                                                 
3 Mets - Metastasis 
4 T value - Size of the original tumor 
5 N value - Degree of nearby lymph nodes involved 
6 M value - Presence of distant metastasis 
List of short-listed variables 
1. CS mets3 at Diagnosis-bone 
2.  CS mets at Diagnosis-lung 
3. CS mets at Diagnosis-liver 
4. CS mets at Diagnosis-brain 
5. Breast Subtype 
6. Vital status recode (study cut-off used) 
7. Age recode  
8. Radiation 
9. Radiation sequence with surgery 
10. T value4 
11. N value5 
12. M value6 
13. Regional nodes positive 
14. CS lymph nodes 
15. CS mets at Diagnosis 
16. CS extension 
17. CS tumor size 
18. Marital status at diagnosis 
19. Regional nodes examined 
20. Estrogen Receptor Status 
21. Progesterone Receptor Status 
22. Survival months 
23. Laterality 
24. Histologic Type ICD-O- 3 
25. Race/ethnicity 
26. Year/Month of Diagnosis 
27. Behavior code ICD-O-3 
28. Surgery of Primary Site 
29. Reason no cancer-directed surgery 
30. SEER cause-specific death classification 
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Out of 134 variables available in SEER, it is crucial to use variables relevant to the 
prediction of breast cancer survivability. Seeking an expert’s opinion for shortlisting the 
variables is crucial. Hence, Dr. Robert Olson, who is a Radiation Oncologist at the BC Cancer 
Agency Centre for the North [83] and Regional Director of Faculty Development, Affiliate 
Assistant Professor, Northern Medical Program, UNBC [84] was consulted. Dr. Robert Olson 
suggested a list of 30 relevant variables out of the 134 variables available (Table 4). These 
variables along with their definitions are listed in Appendix B and were selected in the case 
listing session window (Figure 11). 
 
 
Figure 11. Selecting Variables in SEER*Stat 
 
The ‘Output’ tab allows naming the dataset and the session is executed which produces 
an output table or matrix. The resulting SEER*Stat matrix window could be exported in the 
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CSV format. Before extraction, the data is converted into ASCII text format. A dictionary file 
is auto-generated along with CSV file which provides codes for the variables formatted in the 
matrix. The SEER*Stat case listing session can be saved and reused to run and extract data. 
 
3.2.4 Database 
 
The extracted CSV file is imported into the SQL Server. The database is created based on star 
schema. The dictionary file is used to create dimension tables. Each variable now has primary 
and foreign keys. The master CSV file serves as the fact table using the foreign keys of each 
variable (dimension tables).  
 
3.2.5 Visualization Dashboard 
 
There are several data visualization tools available such as SSRS, Tableau, Power View and 
Qlik View, which can be used to build dashboard and visualize data. As stated earlier, Tableau 
is used primarily because of its versatility, and flexible interface. Tableau is connected to SQL 
Server breast cancer database. The tables are joined to create a view, extending horizontally 
by adding columns of data, as needed. Tableau is further used to cleanse the data such as – 
changing data types, renaming and resetting fields suitable for analysis. Calculated fields, 
formulas, grouping and sets are added via SQL queries. The grouping is done based on the 
level at which analysis is to be performed. Some of the groupings done are as shown in Table 
5.  
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Grouping Dimension Used Level Data elements used 
Age-Range (group) Age-Range 10-year level expect 
80-84 and 85+  
 
(01-09, 10-19, 20-
29, 30-39, 40-49, 
50-59, 60-69, 70-79, 
80-84, 85+) 
Ages 01-04, Ages 05-09, 
Ages 10-14, Ages 15-19, 
Ages 20-24, Ages 25-29, 
Ages 30-34, Ages 35-39, 
Ages 40-44, Ages 45-49, 
Ages 50-54, Ages 55-59, 
Ages 60-64, Ages 65-69, 
Ages 70-74, Ages 75-79, 
Ages 80-84, Ages 85+ 
Race/Ethnicity (group) Race/Ethnicity White, Black, 
Others, Unknown 
Others include: 
American Indian, Aleutian, 
Alaskan Native or Eskimo 
(includes all indigenous 
populations of the Western 
hemisphere), Chinese, 
Japanese, Filipino, 
Hawaiian, Korean, 
Vietnamese, Laotian, 
Hmong, Kampuchean 
(including Khmer and 
Cambodian), Thai, Asian 
Indian or Pakistani, Asian 
Indian, Pakistani, 
Micronesian, Chamorran, 
Guamanian, Polynesian, 
Tahitian, Samoan, Tongan, 
Melanesian, Fiji Islander, 
New Guinean, Other Asian, 
including Asian, 
Pacific Islander, Other 
Regional nodes 
examined (group) 
Regional nodes 
examined 
Exact number (01-
89) of nodes 
examined, 90 or 
more nodes were 
examined, 
No nodes were 
examined, 
No regional nodes 
were removed, 
Regional node 
removal documented 
as dissection, 
Regional lymph 
node removal as 
sampling, 
Regional nodes were 
surgically removed, 
Unknown 
Exact number (01-89) of 
nodes examined:  
Exact 1 nodes examined to 
Exact 89 nodes examined 
Unknown: 
Unknown, 
Unknown whether nodes 
were examined, 
Not Applicable or negative, 
Not stated in patient record 
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Regional nodes positive 
(group) 
Regional nodes 
positive 
Exact number (01-
89) of nodes 
positive, 
90 or more nodes 
were examined, 
All nodes examined 
are negative, 
No nodes were 
examined, 
Positive aspiration 
of lymph nodes(s) 
was performed, 
Positive nodes are 
documented, but not 
specified, 
Unknown 
Exact number (01-89) of 
nodes examined:  
Exact 1 nodes examined 
and tagged positive to Exact 
89 nodes examined and 
tagged positive 
Unknown: 
Unknown, 
Unknown whether nodes 
were examined, 
Not Applicable or negative, 
Not stated in patient record 
 
Table 5. Grouping of Variables for Data Preprocessing 
 
 
The data can be extracted in the Tableau workbook which is a compressed snapshot of 
actual data. It is used to make the data engine work faster and provides faster analytical and 
query performance. The extracted data could be further sliced and diced by using filters and 
parameters such as year of diagnosis, race/ethnicity and state. The dissected data is then 
visualized using workbook, dashboards, and stories. The screenshots of the dashboard are 
presented in section 4.1. 
 
3.3 Breast Cancer Predictive Model 
 
Identifying patterns from the historical data and using them to make predictions forms the basis 
of predictive analysis [86]. Predictive analysis deals with developing models using wide 
varieties of data modeling techniques [87]. Decision trees (C&RT, QUEST, CHAID), Neural 
Networks, Linear Regression, and Support Vector Machines are some of the popular data 
modeling techniques.  
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The breast cancer predictive model is developed from the preprocessed data extracted 
from the SEER database. This model is trained with the existing data of breast cancer patients 
and could be used by doctors to determine the patient’s survival time ranging in months. The 
step by step process of developing a predictive model is discussed in the following subsections. 
However, before developing the predictive model, it is essential to finalize on the technology 
to create the model. For this research IBM SPSS Modeler 18.1 was used. The underlying 
rationale for selecting IBM SPSS Modeler is discussed next. 
 
3.3.1 SPSS Modeler 
 
Many of the studies discussed in the literature [5, 18], have used WEKA [58] as the underlying 
software to design their predictive models. However, with the growing popularity of IBM’s 
SPSS Modeler [88] and SAS Enterprise Miner [89], an inclination towards the commercially 
available tools over the open source ones used earlier was imminent. Amongst the two, IBM’s 
SPSS Modeler is selected for this research. The rationale for this decision was two-fold: 
 Base this research by designing a predictive model of a different, reliable platform to 
increase the probability of any differences one could observe with the techniques used 
to design the predictive models, and 
 The reliability of the brand name of IBM, and the assurance of adequate technical 
support, along with the detailed and publicly available documentation which helped 
address many of the primary concerns. 
IBM SPSS Modeler is a software package used for building predictive models using 
advanced algorithms and data mining techniques, such as decision trees (C&RT, QUEST, 
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CHAID), neural networks, linear regression, and support vector machines. SPSS Modeler 18.1 
is used for this research and has the following features: 
 It has a highly interactive and user-friendly interface. 
 SPSS Modeler can do data preparation for the user and has the capability of automated 
preparation of raw data via the ‘Automated Data Preparation’ (ADP) node.  
 Modeling nodes such as ‘Auto Classifier’, ‘Auto Numeric’ and Auto Cluster’ are 
powerful techniques that can compare several modelling methods and rank them in 
effective order. 
 It helps extract values from a variety of data including structured data, unstructured 
data, and that from other sources such as a database, variable file, statistics file, IBM 
Cognos BI [90] and SAS file. 
 
Once IBM SPSS Modeler was finalized as the platform to create the predictive model, the 
next task was to put it to use and commence designing the predictive model. Although the IBM 
documentation guides creating custom models, the content on a few occasions was ambiguous 
and the documentation, in general, was verbose. Broadly, the following essential tasks were 
identified to accomplish the predictive model: 
 Preparing the data for modeling 
 Determining input and target variables of breast cancer predictive model 
 Selection of modeling techniques for developing the predictive model 
 Training the predictive model 
 Testing the predictive model 
These tasks are described in the following sections. 
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3.3.2 Data Preparation 
 
The SEER data is available from 1973-2013 which was divided into two datasets, one for 
training and the other for validating/testing. The 1988-2003 dataset is selected for training the 
model due to the following reasons: 
 The model needs to be trained on one particular dataset and then tested and validated on 
different datasets, i.e. data outside trained dataset. 
 The training dataset should have data for all shortlisted variable.  
 The range of the number of years to predict survivability in this research is arbitrarily 
set at 10 years. Since the follow-up cut-off date for selected SEER data is December 31, 
2013, the cases registered in 2003 or before are considered. 
Thus, the dataset from 1988-2003 is selected for training the predictive model and the dataset 
for the year 2004 is used for testing and determining the predictive model’s accuracy. 
 
3.3.3 Determining Input Variables 
 
Post data preparation, the subsequent task involved shortlisting relevant variables which have 
predictive power. The independent or target variable’s relation with the input variables 
determines the power of the predictive model. The first screening process of narrowing down 
30 relevant variables out of 134 total variables played an instrumental role in this process. The 
shortlisted variables were relevant if they are the best fit or have predictive power. The target 
or outcome variable is ‘survival months’ which is the dependent variable. The remaining 29 
variables are independent variables and would be checked if they have a relationship with the 
dependent variable, i.e. ‘survival months’. Another important factor required to take into 
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consideration is to select input variables which are available for the selected period (1988-
2003). 
Feature selection modeling technique is used for shortlisting relevant input variables. This 
technique is used during the preliminary stages of analysis to locate variables that are most 
likely to be of interest. The feature selection consists of three steps: Screening, Ranking and 
Selecting. The ‘Feature Selection’ node (Figure 12) is configured to find the rankings of all 
input variables, i.e. important, marginal and unimportant. Variables not available for training 
period are removed from the list of input variables because there is no data for those variables 
to train the model.  
 
 
Figure 12. Feature Selection Model Snapshot 
 
The ‘Feature Selection’ model nugget filters out nine variables, of the 30 total variables, as 
unimportant. The remaining 21 variables are ranked by their importance. By cutting down the 
number of fields in the model, scoring time and amount of data collected in future iterations 
can be reduced [88]. The list of variables according to importance ranking are shown in  
Table 6. The detailed definitions and coding of these variables are listed in Appendix B. 
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Input variables: 
1. Marital Status 
2. Race/ethnicity 
3. Age recode 
4. Laterality 
5. Histologic Type ICD-O-3 
6. Behavior code ICD-O-3 
7. Regional nodes positive 
8. Regional nodes examined 
9. Reason no cancer-directed surgery 
10. Radiation 
11. Radiation sequence with surgery 
12. Surgery of Primary Site 
13. Vital Status recode 
14. Estrogen Receptor Status 
15. Progesterone Receptor Status 
16. T value 
17. N value 
18. M value 
19. Year/Month of diagnosis 
Target variables: 
20. Survival months 
Record ID (unique identifier): 
21. Patient ID 
 
Table 6. List of Variables (Input & Target) for Predictive Modeling 
 
 
3.3.4 Selecting Modeling Techniques 
 
The predictive model is developed using modeling technique(s) which are based on the use of 
algorithms. There are three modeling technique classes in SPSS Modeler, namely 
Classification, Association and Segmentation. Some of the examples of modeling techniques 
in these classes are described in Table 7. Classification models take one or more input fields 
and can predict one or more target variables. Association models find patterns in the data, 
where one or more entities are associated with one or more entities. These models allow a 
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variable to act as input and target both. On the other hand, Segmentation models divide the 
data into clusters that have similar patterns of input variables.  
 The goal of this research is to predict survival months of patients. Survival months is 
of continuous (numeric) data type thus the modeling techniques selection is based on the 
models which allow continuous numeric range target. The classification techniques which 
support continuous numeric range target include Neural Networks, C&R Tree, CHAID, Linear 
Regression, Generalized Linear Regression and Support Vector Machines. 
 
Classification Association Segmentation (clustering) 
Decision Trees: 
C&R Tree, Quest, CHAID, 
C5.0 
Apriori model 
Carma model 
Sequential detection model 
Kohnen Networks 
K-Means clustering 
Two-step clustering 
Anomaly detection 
Regression: 
Linear, Logistic, Generalized 
linear, Cox regression 
Neural Networks 
Support Vector Machines 
Bayesian Networks 
 
Table 7. Modeling Technique Classes 
 
 
The predictive model is built using the modeling techniques classes described above. 
The modeling techniques which complete execution in a reasonable time and have a high 
correlation of variables were selected. The top three classification techniques selected are 
Neural Network, CHAID and C&R Tree.. These techniques are discussed in detail in the 
following sections. 
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3.3.4.1 Neural Network 
 
Neural Networks work by finding unknown and intricate patterns in the data. They resemble 
the human brain as it gains knowledge from the learning process. The basic units called neurons 
are organized in layers. The neurons are connected with different weights, and the network 
learns from training. There are three layers in the neural network, namely, the input layer, 
hidden layers and output layer (Figure 13). The input variables are presented to the input layer. 
The values are propagated from each unit in the hidden layers. The predicted outcome is 
delivered from the output layer. The network learns by examining each record and predicting 
target and making the adjustment to the weights if the prediction is incorrect. This is a recursive 
process and is only stopped if there is a stopping criterion defined before training. The Neural 
Network models are recommended to use if interpretability is not a priority. 
 
Figure 13. Structure of Neural Network 
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It is not easy to understand the underlying process of creating a relationship between the 
target and input variables. There are two types of Neural Network model available in IBM 
SPSS Modeler: Multilayer Perceptron (MLP) and Radial Basis Function (RBF). MLP is made 
up of two or more hidden layers. It is a feed-forward, supervised learning network. It is a 
function of multiple input variables that minimize the prediction error of one or more targets 
[87]. MLP has higher training and scoring time compared to RBF. Further, RBF has low 
predictive power as compared to MLP. Training the Neural Network model is a critical step. 
The model’s accuracy is dependent on the training process. Finding suitable model settings for 
training the Neural Network models is an iterative process. Post data preparation, next step is 
identifying factors such as the type of Neural Network model (MLP or RBF), structure (number 
of hidden layers and number of neurons in each layer), stopping rules, training time, training 
cycles, and ensemble voting if applicable. After training the model, the results are validated 
and the process is repeated if required. The field requirements are simple as there only must be 
at least one target value and one input field [88]. Neural Networks deal with the missing values 
with these two options: 
 Records with missing values are excluded. 
 Missing values are imputed – Continuous fields impute the average value of minimum, 
and maximum values observed. 
 
3.3.4.2 Chi-squared Automatic Interaction Detection 
 
Chi-squared Automatic Interaction Detection (CHAID) is a classification scheme for building 
a decision tree by using chi-square statistics. Decision tree models predict future outcomes 
based on a set of decision rules. Decision trees work best with categorical data elements such 
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as surgery versus non-surgery treatment, married versus unmarried patients, and types of nodes 
involved. The decision trees also relate predictions to the values of continuous variables. 
CHAID uses statistical tests as criteria for evaluating the predictors (input variables). The 
unique feature of CHAID is that it groups variables that are statistically similar to the target 
variable. It also maintains a group of variables that are statistically dissimilar. Taking the 
similar ones into consideration, CHAID finds the best predictor to create first branch of the 
tree. This tree has child nodes which also fall under the statistically similar variables group. 
The tree is completed by continuing this process. The statistical test for grouping similar 
variables is done by using F-test for the continuous target and chi-squared test for the 
categorical target. CHAID not being a binary tree method produces two or more groupings at 
all levels of the tree. The CHAID decision trees are wider than binary tree methods. The 
advantages of using CHAID are: 
 It works for all types of variables. 
 It accepts both frequency and case-weighted variables. 
 It can handle missing values by treating them as a single category. 
The predictions in CHAID are made by following the terminal node of the tree which 
has a specific predicted value associated with it. For numeric target, the terminal node’s 
predicted category is calculated as the weighted mean of the target values for records in the 
node. CHAID works for all types of inputs. Target and inputs can be continuous or categorical 
[88]. 
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3.3.4.3 Classification and Regression Tree 
 
The Classification and Regression Tree (C&RT) model is used when there are multiple inputs 
and one target variable. C&RT groups data into two subsets and repeats the process until 
homogeneous records are grouped together. The subsets split again and process repeats and 
stops when stopping rule is applied or homogeneity is achieved totally. C&RT might use the 
same predictor field at different tree levels. All the splits are binary; thus C&RT is strictly a 
binary tree. It provides the option first to grow the tree and then prune based on cost-complexity 
criteria. This technique requires one or more input variables and exactly one target variable. 
The advantage of using the C&RT modeling node are: 
 It does not require long training time. 
 It is quite adaptive if data has missing values or has a large number of fields. 
The predictions in C&RT are also done by following the tree splits to a terminal node 
of the tree. The terminal node has a specific predicted value associated with it. For numeric 
target, the terminal node’s predicted category is calculated as the weighted mean of the target 
values for records in the node. Both target and input variables can be continuous or categorical 
[88]. 
 
3.3.4.4 Ensemble 
 
Ensemble modeling technique combines multiple individual models to provide better 
prediction accuracy. In literature, it is observed that the researchers use an ensemble of 
different modeling techniques and predict better outcomes as compared to individual models 
[5, 18].  By combining the predictions from multiple models, limitations of individual models 
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can be avoided and thereby result in high accuracy overall. Models when combined in this 
manner perform at least as well as the best of individual models and even better [88]. 
Some of the difficulties faced when developing the ensemble model are finding out the 
combination of models to be used. Individual models selected for ensemble should have high 
prediction accuracy and should not overfit [64]. There are different rules for combining 
predicted values from individual models to compute ensemble score value. For categorical 
targets, combining rules available are voting, the highest probability and highest mean 
probability. For continuous targets, averaging is the only combining rule. Since the target 
variable is a continuous variable, an ensemble score is computed by averaging the values of 
individual models. The ensemble prediction is calculated by using the following formula 
(Equation 1): 
?̂?𝑖,𝑀 =
1
𝑀
∑ ?̂?𝑖,𝑚
𝑀
𝑚=1
 
Equation 1. Ensemble Prediction Equation 
 
where,  ?̂?𝑖,𝑀 is the final predicted value of case i 
 ?̂?𝑖,𝑚 is the m
th base model’s predicted value for case i 
 
A hypothesis is proposed that Ensemble model outperforms the individual models, i.e. Neural 
Network, C&RT and CHAID models. After selecting the modeling techniques, the predictive 
model is built. The following sections present the three phases of building a prediction model 
in detail.  
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3.3.5 Training Predictive Model 
 
Figure 14 is a snapshot of the training phase of the predictive model built in IBM SPSS Modeler 
[88]. The model description is as follows: 
 
 
Figure 14. Predictive Model Training snapshot 
 
 Data (1988-2003) node is the Excel Source node. Excel Source node allows importing any 
Excel workbook available on the local machine. The import can be customized by selecting 
a specific range of cells defined in the Excel worksheet or by selecting a specific worksheet 
from the entire workbook. The variable names can be changed in Source node settings. The 
Excel worksheet imported for training the model has SEER extracted breast cancer data 
from 1988-2003.  
 Type node: The Source node is connected to a Type node which defines the measurement 
level for each variable such as Nominal, Ordinal, Continous, Categorical, Flag or Typeless. 
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Type node also defines the role of each input field such as Input, Target, Both (Input & 
Target), None, Partition, Split, Frequency, and Record ID. Input fields are the predictors 
and Target is the field that the model has to predict. In the model, there exist a total 21 
fields, out of which there are 19 predictors (input), 1 Target (Survival months) and 1 Record 
ID (Patient ID). 
 Modeling nodes: The Type node is connected to three modeling nodes - Neural Network, 
CHAID and C&R Tree. The selected modeling nodes are classification models which use 
one or more predictors to predict the target. Each modeling node has field option where 
variables are specified as input and target. However, since Type node is used, there is no 
need to address the field specification in modeling nodes.  
 When the model completes its execution, the resulting nuggets are added to stream for each 
modeling node (Figure 14). The nuggets contain complete information of the model (rules 
and equations developed) and accuracy of the independent model formulated by IBM SPSS 
Modeler. The model summary can be browsed by double-clicking the generated nuggets. 
 Ensemble node is added to the stream to create an ensemble of these techniques. For this 
purpose, the modeling nuggets are connected to the ensemble node as shown in Figure 14. 
The ensemble model provides minimal options such as selecting a target field for ensemble, 
filtering out the fields generated by ensemble models and calculating standard error. Figure 
15 shows Ensemble node settings, ‘Survival Months’ is selected as the target and the option 
‘Filter out fields generated by ensemble models’ is unselected to get individual models’ 
prediction along with ensemble. An option for calculating the standard error was also 
chosen. 
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Figure 15. Ensemble Node Setting 
 
On completing execution, each modeling technique node creates nuggets (diamond-
shaped) except for the Ensemble which is a combining rule model. Each nugget has the model 
summary which displays a number of variables used, predictor importance, stopping rules, and 
number of layers. The nugget summary also has the training accuracy of each modeling 
technique. The following training accuracies were observed for selected modeling techniques 
of the predictive model: 
 Modeling Techniques 
Neural Network CHAID C&RT 
Training Accuracy 82.9% 82.1% 82.0% 
 
 Table 8. Training Accuracy 
 
In the Analysis node, training and actual outcomes are analyzed for the individual 
model as well as Ensemble model. The statistical measure used to compare is mean, minimum, 
maximum, mean absolute error and standard deviation. Once, the model has trained it is now 
ready to be tested and validated. The next section discusses testing and validation methods 
used in this research. 
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3.3.6 Testing and Validation of Predictive Model 
 
Figure 16 is a snapshot of the testing phase of the developed predictive model. The model is 
now tested for the cases outside its training range, that is, cases registered in 2004. The source 
node now represents the testing dataset, i.e. Data (2004). The output of individual models and 
ensemble model can be captured in different ways:  
 Table - a static matrix window generated in IBM SPSS Modeler 
 Analysis node - this node allows testing the measured (predicted) values against the 
known result  
 Excel node - it generates an Excel sheet with predicted values  
 The additional nodes used here are Transpose node to transpose columns into rows, 
and Type node to extract data into Excel sheet. 
 
Figure 16. Predictive Model Testing Snapshot 
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Figure 17. Execution of Excel Output Node 
 
For testing the model with all cases diagnosed in 2004 together, Excel output node is 
executed (as shown in Figure 17) which generates an Excel sheet with predicted outcomes for 
each record. This newly generated Excel sheet is then used to compare measured values with 
actual values (survival months) to validate the accuracy of the predictive model. The results of 
the validation of the model are discussed in the next chapter. 
The method presented above works well for testing a large number of cases together. 
However, if the user wants to predict survival months for one individual case, they could use 
the User Input to enter values of all variables and use the same predictive model as a calculator. 
Figure 18 is a snapshot of using the predictive model as a calculator with the User Input node 
instead of the source node. Figure 19 shows the User Input node window. The definitions and 
coding of each variable are attached in Appendix B. 
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Figure 18. Predictive Model as calculator for individual case 
 
 
 
Figure 19. User Input Node Snapshot 
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3.4 Summary 
 
In this chapter, a detailed description of the five main tasks, namely, data extraction, 
data analysis, data visualization, predictive modeling, and evaluation of predictive model has 
been presented. These tasks collectively contribute to accomplishing the implementation of the 
predictive model along with visualization dashboard. A comprehensive understanding of 
several predictive modeling techniques along with the rationale behind choosing the right tools, 
technologies, and approaches to accomplish the primary contributions have also been 
presented. The experiments and analysis of results of both dashboard and predictive model are 
presented in the next chapter.  
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4. Experiments and Results  
 
In this chapter, the experimental results of data analysis and predictive techniques are 
presented. The first section demonstrates the data analysis and visualization reports and 
dashboard representing forty years of breast cancer data. The second section demonstrates the 
accuracy of the predictive model and comparison study of predictive model’s accuracy on 
different datasets. 
4.1 Data Analysis and Visualization 
 
For visual analytics, the pre-processed SEER data is first imported to SQL Server to create 
‘Cancer’ database in a format suitable for analysis. Tableau is connected to the Cancer 
database, and the tables are joined to create a virtual table, extending horizontally by adding 
columns of data needed. The data is further cleaned up (by changing data types, renaming & 
resetting fields, wherever needed) to prepare data for analysis. Data is analyzed by adding new 
calculated fields, formulas, grouping and sets by writing SQL queries. The data is sliced and 
diced by using filters on measures and dimensions and creating parameters. The data is then 
visualized using workbook, dashboards and stories. The dashboard and dynamic reports use 
the views and tables created in the SQL Server database.  
The subsequent sections present each of the reports generated using Tableau [75]. 
Tableau story [91] and story points are used for visual analytics of breast cancer data. Tableau 
story is a sequence of visualizations that work together to convey the findings. Each sub-report 
is also called a story-point. The top-level dashboard provides an overview of the KPIs and 
includes navigation controls including a tab panel (Figure 20) which allows switching between 
breast cancer metastasis, TNM system, cases by geo-mapping, geo-mapping by race/ethnicity, 
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cases by race and age range, lymph node involvement, incidence/mortality, survival/mortality 
and anatomy dashboards.  
 
Figure 20. Breast Cancer Dashboard Story Point Panel 
 
 
4.1.1 Breast Cancer Survivability Dashboard 
 
 
Figure 21. Breast Cancer Survivability Dashboard 
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The main dashboard (Figure 21) contains five sub-reports/story points which can be filtered by 
year of diagnosis (1973-2013). The first table shows the total number of cases by vital stats 
(i.e. Alive or Dead). Out of the total of 1,037,457 cases registered in SEER over the forty-year 
period, 241,677 cases died due to breast cancer and rest were tagged Alive at the study cut-off 
date (i.e. December 31, 2013). Amongst all the causes of death in females (including cancer 
and non-cancer related deaths), breast cancer is the third highest cause of death after lung-
bronchus cancer and diseases of the heart. For registered breast cancer cases, a similar kind of 
categorization is represented by marital status at diagnosis. The analysis shows that the 
majority of women (597,909 cases) were married at the time of breast cancer diagnosis. This 
is followed by widowed, single (never married), divorced, separated and unmarried in 
descending order. There are about 44,700 cases whose marital status was unknown. All the 
cases are further categorized by age-range and survival years. For this table, only cases that are 
tagged Alive as of cut-off date are used. Out of total ‘Alive’ tagged cases, a majority of the 
patients who survived more than 10 years are in age-range of 50-59, followed by 40-49 and 
60-69 years. Brandt et al. [92] also concluded that women aged under 40 and above 80 years 
at the time of diagnosis have a poor survival rate independent of any factors. This is consistent 
with observation made by the dashboard.  
 
4.1.2 Breast Cancer Metastasis 
 
The Breast Cancer Metastasis (Figure 22) dashboard consists of five sub-reports which can be 
filtered by year of diagnosis and alive cases or cases who died. The data for metastasis is only 
available from 2010 onwards. The vital stats table shows that out of a total of 258,125 cases 
registered with metastasis, 13,499 patients had died due to breast cancer and rest were alive at 
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the study cut-off date. The four pie-charts display information regarding metastasis to bone, 
brain, liver and lung. Cases are categorized based on whether the breast cancer metastasized, 
no metastasis and unknown. The number of unknown cases is low and hence is not included 
in the pie-charts. It is noted that the majority of the cases who died had their breast cancer 
metastasized to the brain, followed by lung, liver and brain, respectively. Similarly, ‘Alive’ 
cases can be selected to observe the impact of metastasis. 
 
Figure 22. Breast Cancer Metastasis (Data 2010+) 
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4.1.3 Breast Cancer TNM System 
 
The Breast Cancer TNM System dashboard (Figure 23) consists of three sub-reports 
categorized by T, N, M values for cases registered from 1988 to 2003. The bar graph views 
can be switched by age-range, marital status and year of diagnosis by using the radio buttons 
on the top-right of the dashboard. A massive jump in the number of cases registered is observed 
in 1992 and 2000. This is because new SEER registries were added to the SEER database in 
these two years [93]. Figure 23 consists of three sub reports which present cases by T value 
(size of the original tumor), N value (degree of nearby lymph nodes involved) and M value 
(presence of distant metastasis). Each value type has different categories such as T0, T1, TX, 
N0, N1, Nx, M0, and M1. Each point in the charts has tooltips to display more information and 
can be clicked to open relevant web pages. 
The dashboard shows that for all cases diagnosed in 1988-2003, the maximum number of cases 
have T1 value (i.e. one primary tumor) followed by the T2 value (i.e. two primary tumors). On 
the other hand, the maximum number of cases did not have any nearby lymph nodes containing 
cancer (N0 value) and no distant cancer metastasis was found (M0 value). When the view is 
switched, and cases are categorized by age range, the dashboard shows that 50-59 age range, 
with maximum number of cases, 58.28% of cases have T1 value, followed by T2 (24.04%), 
TX, Txa, T3, T4d, T4b, T4a, T0, Tis, and T4c. The N value charts show that for the 50-59 age 
range, 60.46% cases have N0 value followed by N1x (16.20%), N1b, NX, N1a and N2. The M 
value chart shows 93.29% of cases in the 50-59 age range have M0 value, i.e. no distant 
metastasis. Similar trends are observed when the view is switched to marital status. 
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Figure 23. Breast Cancer TNM System 
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4.1.4 Geographic Distribution of Breast Cancer Cases by Race 
 
 
Figure 24. Geographic Distribution of Breast Cancer Cases by Race 
 
The Geo-mapping by Race/Ethnicity dashboard (Figure 24) is a dynamic map showing 
the case concentration and changes over the years. The pie-charts categorize the cases by 
Race/Ethnicity: White, Black, and Others, the latter being a clickable option which drills down 
to display the distribution of cases by all races in data. A “play/pause” feature allows a dynamic 
display of the changes over the years (1973-2013). The State parameter can be used to filter 
and select one or more States and observe the trend for selected regions. 
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4.1.5 Breast Cancer Cases by Race and Age Range 
 
 
Figure 25. Breast Cancer Cases by Race and Age Range 
 
Breast cancer cases by race and age-range are shown in Figure 25. The bubble chart 
shows the cases categorized by the races other than white and black race which are filtered 
from the Geo-mapping dashboard. A tabular breakdown of cases by age range shows that the 
50-54 age range has the highest number of cases followed by 45-49 and 55-59. This dashboard 
can be further filtered by year of diagnosis, race and state parameters. 
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4.1.6 Breast Cancer Anatomy Dashboard 
 
 
Figure 26. Breast Cancer Anatomy 
 
The Breast Cancer Anatomy dashboard (Figure 26) consists of four sub-reports/story points. 
The data used is for the period 1973-2013 except for breast subtype for which data is only 
available from 2010 onwards. The tables represent breast cancer cases categorized by laterality, 
examined and positive regional nodes, and breast subtype. The highlighted cells in each table 
display the highest number of cases in that category. For example, in most cases, the tumour 
originated on the left side of the body/organ. The regional nodes are the lymph nodes present 
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in the armpits [94]. For a maximum number of cases, regional nodes were examined (1-89 in 
number) to test cancer cells involvement; 50% of these were negative (absence of cancer cells). 
The breast subtype is further categorized by ER (Estrogen-Receptor-positive) status and PR 
(Progesterone-Receptor-positive) status. The analysis shows that a maximum number of cases 
have positive ER and PR status and the breast subtype is Her2-/HR+ (Human epidermal growth 
factor receptor 2 negative/Hormone Receptor-positive).  
 
4.1.7 Lymph Node Involvement Dashboard 
 
The lymph node involvement in breast cancer is shown in Figure 27. The presence of cancer 
cells in a lymph node under arms acts as an indicator of increased risk of cancer spreading in 
the body [94]. Higher the number of lymph nodes containing cancer cells, higher is the 
seriousness of cancer. Physicians often use the count of lymph nodes involved to design 
treatment plans. The data for this dashboard was only available from 2004 onwards. The cases 
registered before 2004 are categorized as Unknown. The axillary/regional lymph nodes 
involvement is observed in a maximum number of cases. Axillary lymph nodes dissection is 
performed on axillary nodes which are suspected to have cancer cells in them. Since, axillary 
nodes constitute around 75% of the lymph nodes drain from breasts, the analysis indicated that 
from over 88 thousand cases of breast cancer reported, axillary/regional lymph nodes 
involvement accounted for almost one third of them, thus making axillary/regional lymph node 
involvement as the top category in the number of cases. No distant metastasis was found in a 
maximum number of cases, i.e. the cancer is not spread to other parts for such cases. The 
prognosis factors table is displayed in the prognostic indicators table. Positive/elevated topped 
the list of prognostic indicators. 
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Figure 27. Lymph Node Involvement in Breast Cancer Cases 
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4.1.8 Geographic Distribution by Incidence/Mortality cases of Breast Cancer Cases 
 
 
Figure 28. Geographic Distribution by Breast Cancer Incidence Cases 
 
 
Figure 29. Selection panel - Breast Cancer Incidence/Mortality Cases 
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Geographic distribution by Incidence/Mortality provides Incidence and Mortality cases 
mapping by State and County as two separate dashboards (Figure 28 and Figure 30) either of 
which can be accessed by switching the views (Figure 29). Both dashboards can be filtered by 
the year of diagnosis and the State. Figure 28 and Figure 30 display breast cancer incidence 
and mortality cases for the year 2013 and shows that California had the highest number of 
breast cancer cases, followed by Washington, Michigan, Kentucky, and Connecticut. The pink 
plots denote the number of cases only and don’t take into consideration the population of the 
states while determining the rankings by state. The dashboard helps identify that incidence 
count of breast cancer is not directly proportional to population. This is evident from the fact 
that the population of Michigan in 2013 was higher than the population of Washington, yet 
Washington had higher incidence count.    
The mortality (i.e. cases died due to breast cancer) trends for the year 2013 are not 
coherent with the incidence trends observed for the same year. The state of California had the 
highest mortality count followed by Kentucky, Michigan and Connecticut. Alaska had the 
lowest mortality count. The mortality count, however, has some similarities, especially with 
respect to their dependency on the total population count for the states for that given year. This 
is evident from the fact that, Kentucky, like Washington, had a total population lower than that 
of Michigan, yet had higher mortality count than Michigan. 
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Figure 30. Geographic Distribution by Breast Cancer Mortality Cases 
 
 
4.1.9 Breast Cancer Survival/Mortality rate by Age Range 
 
A box and whisker visual as shown in Figure 31 is a chart type which displays data distribution 
by quartiles. The box represents the value between first and third quartiles. The whiskers (A – 
lower whisker and B – upper whisker) represent the distance between the lowest value to the 
first quartile and the fourth quartile to the highest value. At the median (E) the box colour 
changes and becomes lighter showing the upper and lower quartiles (D and C respectively). 
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The lower (C) and upper hinge (D) are medians of the lower and upper half of the data [95]. 
Each box and whisker is for specific age range showing the distribution of cases by incidence 
or mortality rates. 
 
  Figure 31. Box and Whisker Visual 
 
 
Figure 32. Breast Cancer Survival Rate by Age Range 
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Figure 32 shows a box-whisker chart of the survival rate of by age-range for California (1973-
2013). The survival rate is the ratio of cases tagged Alive to the total number of cases 
registered. The survivability (by years) is plotted against age-range and survival rate. The 
median survival rate is highest for age-range 60-69 (82.2%) followed by the age-ranges 50-59, 
40-49, and 70-79. There is an exception, and age range 10-19 has a 100% survival rate because 
of the low number of cases (12).  
 
 
Figure 33. Selection panel - Breast Cancer Survival/Mortality Rate 
 
 
 
A similar dashboard is shown for the mortality rate (Figure 34) for the same 
geographical area. The incidence and mortality rate are two separate dashboards either of 
which can be accessed by switching the views (Figure 33). The mortality rate is the ratio of 
cases tagged ‘Dead’ to the total number of cases registered. The median mortality rate is 
highest for age-ranges 85+ (28.6%) and 30-39 (28.2%). The age-range 60-69 has the lowest 
mortality rate of 17.7%. Each plot of the box-whisker chart shows the total number of cases, 
Alive/Dead cases, and survival/mortality rate for selected survivability period. The 
survivability period ranges from 1 to >10 years. The bottom point on each box-plot displays 
the lowest survivability period and increases in the top to bottom fashion (Figure 32). However, 
the pattern reverses in mortality rate dashboard (Figure 33), the top point of each box-plot starts 
with the lowest survivability period and increases in the top to bottom fashion. 
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Figure 34. Breast Cancer Mortality Rate by Age Range 
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4.1.10 Summary of Data Analysis and Visualization Results 
 
An interactive, end-to-end process to cleanse, integrate, analyze, and visualize 
enormous amount of data is developed. The purpose is to enable healthcare professionals, 
patients and policymakers with a better understanding of the hidden patterns in data, which in 
turn, could be useful to to improve the quality of healthcare collectively. Forty years of breast 
cancer data (over one million records) extracted from the SEER database was used to 
demonstrate the analytical power of data visualization. The research approach involved using 
several data preprocessing techniques on the raw data followed by a selection of the relevant 
30 variables, out of a total of 134 variables, before feeding the processed data to the SQL Server 
for analysis. Tableau was used for understanding and interpreting the data along several 
dimensions. Dynamic reports generated using the drill-down capabilities of the dashboard 
provide insights at a finer granularity. The dashboard shows incidence and mortality trends and 
highlights the underlying patterns observed in breast cancer patients which could be used to 
support clinical decisions made by physicians in formulating treatment plans. The dashboard 
is scalable and capable of integrating new data in real-time. Although SEER data from the US 
currently power the dashboard, it can be configured to use data from other sources as well. A 
better understanding of the incidence and mortality trends could potentially guide data-driven 
resource allocation. Physicians could also use this information to educate patients and create 
more awareness about the disease. 
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4.2 Predictive Modeling 
 
The predictive model is trained with the breast cancer dataset, consisting of 400,000 patients 
registered from 1983-2003. The dataset is obtained by performing pre-processing and 
transformation of SEER dataset. The variables used to train the model are selected by using 
the feature selection algorithm. Twenty-one variables are selected out of 134 total variables 
available from the SEER. The model uses CHAID, C&RT, Neural Network, and Ensemble 
modeling techniques. Equal weights are assigned to selected models and Ensemble score is 
generated by averaging. The outcome variable ‘Survivability’ refers to the survival time (in 
months) of each patient. The performance metrics used are average and the accuracy. The 
metrics and graphs are computed by using Tableau. 
In the following sections, graphs showing a comparison of actual and measured 
(predicted) average survival months are plotted by age range, marital status, positive to 
examined regional nodes ratio (percentage), radiation sequence surgery, ER status, PR status 
and Behavior code ICD-O-3. Similarly, a comparison of the accuracy of individual modeling 
techniques and ensemble modeling technique is plotted for the same variables. The results are 
presented for cases tagged as ‘Dead’ on the cut-off date. According to SEER variable 
description cases tagged as ‘Alive’ are the cases who died after the follow-up cut-off date, i.e. 
December 31, 2013. The noted survival months of ‘Alive’ cases is not their actual survival 
months as they were not followed up after cut-off. Thus, only cases tagged as ‘Dead’ at cut-
off date are used to validate the predictive model’s accuracy.  
The developed predictive model is tested for cases registered in the year 2004 which is 
outside trained period (1988-2003) of the model. This dataset is selected for testing and 
validating the predictive model due to the following reasons: 
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 The cut-off date of study is 2013 and cases diagnosed in 2004 are followed up till 2013 
which gives survivability range from 1 to >10 years. 
 The majority of cases fall under 10 and >10 years survivability period as shown in the 
visualization dashboard (Figure 21). 
Thus the dataset for the year 2004 has a maximum number of cases in any calendar 
year outside the training period. Additionally, the same dataset yields all survivability ranges 
which makes it apt to select it for testing and experimentation purposes. There are a total of 
55,268 cases registered in 2004 (only cases with the exact month of diagnosis are included). A 
total of 46,365 cases are tagged ‘Alive’ at the cut-off date, and 8,903 cases are marked ‘Dead’ 
at the cut-off date. 
 
Figure 35. Vital Status comparison (2004) 
 
The vital status statistics of actual and predicted model’s output (i.e. measured7) are 
compared in Figure 35. For cases diagnosed in 2004, 83.39% of cases are tagged ‘Alive’ and 
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16.61% are tagged ‘Dead’ at the cut-off date. The predictive model developed predicts 82.78% 
of cases as ‘Alive’ and 17.22% as ‘Dead’ as of the cut-off date (December 31, 2013) thus 
demonstrating accuracy of 99.26% and 96.45%, respectively. 
 
4.2.1 Comparison of Average Survival Months (Actual vs Measured)  
 
The average survival months for the following experiments is calculated by using the formula 
(Equation 2): 
 
Average Survival Months =
Sum of measured Survival Months
Total number of cases
 
Equation 2. Average Survival Months 
 
Figure 36 shows measured (predicted) survival months by each selected modeling 
technique and their ensemble. Actual survival months (average) of cases registered in the year 
2004 and tagged ‘Dead’ at cut-off date, as shown in the yellow bar, is 42 months. Both 
Ensemble and CHAID measured survival months (average) as 45 months which is closest to 
actual survival months. C&RT and Neural Network predicts average survival months of 33 
and 56 respectively. Overall, Ensemble is performing best along with CHAID. C&RT and 
Neural Network modeling predictions are off from actual average survival months. 
In the following sections, graphs of actual vs measured survival months are plotted as 
trend-lines. Each line in the graphs show the trend of average predicted survival months of 
each model (C&RT, CHAID and Neural Network), and their Ensemble along with actual 
survival months (denoted by Survival Months). The bars in each graph display the number of 
cases falling under the specific category, i.e. such as age-range, marital status, and lymph node 
involvement. Next, the performance of individual modeling techniques is observed. 
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Figure 36. Average Survival Months (2004) 
 
 
From Figure 36, it is evident that Neural Networks do not demonstrate higher accuracy 
(i.e. 66%) in comparison to the other modeling techniques used. This is likely due to the 
following:  
The training dataset used for training (from the years 1988-2003) had values for T, N, 
and M variables. On the contrary, for the testing dataset (2004 and onwards) the values of 
these variables are missing. Neural Networks tend to learn more and extract better knowledge 
by observing trends in the datasets [88]. Neural Networks relative predictor importance8 is 
not uniform in its training. Hence, an inconsistent data across training and testing dataset 
resulted in lower accuracy. Other modeling techniques perform better even with the missing 
                                                 
8  “Predictor importance is determined by computing the reduction in variance of the target attributable to each 
predictor, via a sensitivity analysis” [88]. 
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value of T, N and M variables because they give equal preference to all the variables (i.e. equal 
predictor importance to all predictors). 
To validate the above hypothesis, a new experimentation was performed by eliminating 
the T, N and M variables from the training dataset for all the modeling techniques.  The results 
from this experiment (Figure 37) confirm the hypothesis stated above. Neural Networks 
produced higher accuracy in comparison to the other modeling techniques (Table 9). 
 
 
Figure 37. Average Survival Months (2004 - excluding TNM variables) 
 
 
Accuracy (%) 
 
Modeling Techniques 
Ensemble CHAID C&RT Neural Network 
81 74 74 95 
 
Table 9. Accuracy of Modeling Techniques 
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4.2.1.1 Average Survival Months by Age Range 
 
 
Figure 38. Average Survival Months by Age Range (2004) 
 
Figure 38 compares actual and measured average survival months by age range 10 to 85+ for 
cases registered in 2004 which are tagged ‘Dead’, at the cut-off date. The bars in the chart 
display the number of cases for each age range. Approximately 43% of cases tagged ‘Dead’ at 
cut-off date, fall under the 45-64 age range. The actual survival months varies over different 
age ranges. Cases with age 85 and above have lowest survival months, i.e. 28 months. The 
graph shows both Ensemble and CHAID performing closest to the actual survival months and 
also overlap at few data points. However, Ensemble performs better than C&RT for age 70 
and onwards. C&RT, on the other hand, performs best for lowest and highest age range 
categories. Neural Network predicts high survival month as compared to actual overall age 
ranges. 
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4.2.1.2 Average Survival Months by Marital Status of patient 
 
 
Figure 39. Average Survival Months by Marital Status (2004) 
 
 
Figure 39 compares actual and measured average survival months by marital status (married, 
single, widowed, divorced, separated and unknown) for cases registered in 2004 which are 
tagged ‘Dead’, at the cut-off date. The bars in the chart displays a number of cases for each 
marital status. About 45% of cases tagged ‘Dead’, at cut-off date, are married at diagnosis. The 
actual survival months vary by marital status. Widowed cases have the lowest survival months, 
i.e. 35 months. The graph shows both, Ensemble and CHAID predict closest to the actual 
survival months. The trend lines overlap for divorced cases. C&RT predicts low survival 
months as compared to other techniques. However, Neural Network predicts in range of 45-60 
91 
 
months when actual survival months range from 35-46 survival months. Overall, CHAID and 
Ensemble perform closely. 
 
4.2.1.3 Average Survival Months by Positive to Examined Nodes Ratio 
 
 
Figure 40. Average Survival Months by Positive to Examined Regional Nodes Ratio (2004) 
 
Figure 40 compares actual and measured average survival months by the ratio of positive to 
examined regional nodes for cases registered in 2004 which are tagged ‘Dead’ at the cut-off 
date. The bars in the chart displays the number of cases with the positive to examined regional 
nodes ratio. Amongst the cases with examined nodes, 33% cases have no positive regional 
nodes. The actual survival months is lowest for cases with unknown nodes examined i.e. 30 
months. The graph shows that the Ensemble performs better than other models for cases having 
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70% or less positive to regional nodes ratio and cases having no positive node at all. CHAID 
performs better for cases having 81-90% and unknown positive to regional nodes ratio. Neural 
Network predicts survival months in a range of 49-61 months when actual survival months 
ranges from 30-53 survival months. 
 
4.2.1.4 Average Survival Months by Radiation and Surgery Sequence 
 
Figure 41 shows the case counts and survival months’ distribution by radiation and surgery 
sequence of cases registered in 2004 which are tagged ‘Dead’, at the cut-off date. The bars 
show a number of cases which had radiation and surgery performed categorized as – 
intraoperative radiation therapy, intraoperative radiation with other radiation given before or 
after, sequence unknown yet both surgery and radiation are given, radiation both before and 
after surgery, radiation before surgery, radiation after surgery and no radiation and/or surgery. 
A maximum (67%) number of cases tagged ‘Dead’ did not have radiation and/or surgery 
performed followed by 32% of cases who received radiation after surgery. The actual survival 
months is lowest for cases who died without radiation or surgery, i.e. 37 months. Both CHAID 
and Neural Network predict 42 and 43 months for such cases, respectively. Next, for cases 
which had radiation after surgery have 51 survival months, highest survival months amongst 
all other categories. Ensemble and CHAID predict 50 and 52 survival months, respectively. 
C&RT and Neural Network predicted survival months are off the actual range. Both are 
ranging between 32-37 and 54-60 months, respectively.  
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Figure 41. Average Survival Months by Positive to Radiation and Sequence Surgery (2004) 
 
 
 
4.2.1.5 Average Survival Months by Estrogen and Progesterone Receptor Status 
 
Figure 42 shows actual and measured average survival months are plotted by ER status for 
cases registered in 2004 which are tagged ‘Dead’ at the cut-off date. The status is recorded as 
– positive, negative, borderline and unknown. 52% of cases tagged ‘Dead’, at cut-off date, 
have positive ER status and 30% cases have negative ER status. The actual survival months 
recorded varies from 32-50 months. Cases with unknown and negative ER status have the 
lowest survival months, i.e. 31 and 33 months respectively. Cases with positive ER status have 
the highest survival months, i.e. 50 months. CHAID (47 months) performs better than 
Ensemble (46 months) and other models for such case. For cases having negative ER status, 
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C&RT predicts 35 months compared to actual survival months (33 months). Neural Network 
predicts survival months ranging from 49-56 months over all ER status available. 
 
Figure 42. Average Survival Months by Estrogen Receptor Status (2004) 
 
Next, Figure 43 compares the actual and measured average survival months by PR status 
which is recorded as – positive, negative, borderline and unknown. 42% of ‘Dead’ cases have 
negative PR status, and 38% of cases have a positive PR status. The actual survival months 
recorded varies from 33-52 months. Cases with unknown and negative PR status have the 
lowest survival months, i.e. 32 and 37 months, respectively. The graph shows that for the 
maximum number of cases (negative PR status), C&RT performs best with 34 survival months 
as compared to 37 actual survival months. The highest survival months recorded is 52 months. 
CHAID and Neural Network perform best with 47 and 57 survival months.  
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Figure 43. Average Survival Months by Progesterone Receptor Status (2004) 
 
 
4.2.1.6 Average Survivability by Behavior Code ICD-O-3 
 
 
Figure 44. Average Survival Months by Behavior Code ICD-O-3 (2004) 
 
In Figure 44, actual and measured average survival months are compared by behavior type for 
cases registered in 2004 which are tagged ‘Dead’ at the cut-off date. The cases are categorized 
as malignant (invasive) and carcinoma in situ (non-invasive).  97% of cases tagged ‘Dead’, at 
cut-off date, have the malignant tumor and invasive primary breast cancer. The Ensemble and 
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CHAID models perform best with 45 and 46 average predicted survival months, respectively, 
compared to 41 actual average survival months. Neural Network model performs best for cases 
which have carcinoma in situ behavior type. 
 
4.2.2 Comparison of Accuracy of Modeling Techniques 
 
The accuracy of the experiments is calculated by using the formula (Equation 3)- 
 
Accuracy = {1 − abs {
(Actual Survival Months –  Measured Survival Months)
Actual Survival Months
 }} ∗ 100 
Equation 3. Accuracy 
 
 
Figure 45. Accuracy of different modeling techniques (2004) 
 
 
Figure 45 compares accuracies of CHAID, C&RT, Neural Network and Ensemble 
modeling techniques. Ensemble has the highest accuracy when compared at aggregated year 
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level, i.e. 2004. This is followed by CHAID and C&RT with 92% and 80%, respectively. 
Neural Network has the lowest accuracy, i.e. 66%.  
In the following sections, the accuracy of the predictive model is plotted as trend-lines 
where each line shows the accuracy of the individual modeling technique (C&RT, CHAID and 
Neural Network), and their Ensemble. The bars in each graph display the number of cases 
following under the specific category i.e. such as age-range, marital status, etc. 
 
4.2.2.1 Accuracy by Age Range 
 
 
Figure 46. Accuracy by Age Range (2004) 
 
Figure 46 shows the comparison of the accuracy of predictive models with respect to age for 
cases registered in 2004 which are tagged ‘Dead’ at the cut-off date. The age ranges from 10 
to 85+. The bars in the chart displays a number of cases for each age range. 15% of total cases 
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tagged ‘Dead’ fall under 80-85+ age range. The graph shows interesting trends, CHAID and 
Ensemble model has the highest accuracy overall but drops down for age 75 and onwards. 
C&RT model on the other hand has the highest accuracy of 95%, 91% and 100% for the age 
range 10-24, 80-84 and 85+, respectively. Neural Network prediction ranges from 29-79% 
which is lowest compared to other models. Ensemble outperforms the CHAID model for some 
age-ranges. 
 
4.2.2.2 Accuracy by Marital Status  
 
 
Figure 47. Accuracy by Marital Status (2004) 
 
Figure 47 shows the comparison of the accuracy of predictive models by marital status 
(married, single, widowed, divorced, separated and unknown) for cases registered in 2004 
which are tagged ‘Dead’ at the cut-off date. The bars in the chart displays a number of cases 
for each marital status. The graph shows that 45% of died cases are married, 22% cases are 
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widowed, and 11% are divorced. Ensemble and CHAID have the highest accuracy for married 
cases. CHAID has the highest prediction accuracy of divorced cases, i.e. 93%. C&RT has the 
highest prediction accuracy for widowed cases. Neural Network tends to have low prediction 
accuracy ranging from 47-82%. 
 
4.2.2.3 Accuracy by Positive to Examined Nodes Ratio  
 
 
Figure 48. Accuracy by Positive to Examined Ratio (2004) 
 
 
Figure 48 shows the comparison of the accuracy of predictive models by the ratio of positive 
to examined regional nodes for cases registered in 2004 which are tagged ‘Dead’ at the cut-off 
date. The bars in the chart displays a number of cases with positive to examined regional nodes 
ratio. Amongst the cases with examined nodes, 67% cases have positive to examined regional 
nodes (ranging 1-100%). The Ensemble has the highest accuracy for cases having 70% or less 
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positive to regional nodes ratio and cases having no positive nodes. CHAID and C&RT have 
the highest accuracy for cases having 81-90% and unknown positive to regional nodes ratio. 
Neural Network prediction accuracy ranges from 34-84%. 
 
4.2.2.4 Accuracy by Radiation and Surgery Sequence  
 
 
Figure 49. Accuracy by Radiation Sequence Surgery (2004) 
 
 
Figure 49 shows the case counts and survival months’ distribution by the radiation and surgery 
sequence of cases registered in 2004 which are tagged ‘Dead’ at the cut-off date. The bars show 
a number of cases which had radiation and surgery performed categorized as – intraoperative 
radiation therapy, intraoperative radiation with other radiation given before or after, sequence 
unknown yet both surgery and radiation are given, radiation both before and after surgery, 
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radiation before surgery, radiation after surgery and no radiation and/or surgery. The graph 
shows that 66% of cases tagged ‘Dead’ did not have radiation and/or surgery performed 
followed by 32% of cases who got radiation after surgery is performed. Ensemble and CHAID 
have the highest accuracies ranging from 81-98% and 83-99% respectively. Neural Network 
has the lowest accuracy overall, except for cases categorized as radiation after surgery. C&RT 
has the lowest accuracy for cases categorized as radiation after surgery. 
 
4.2.2.5 Accuracy by Estrogen and Progesterone Receptor Status 
 
 
Figure 50. Accuracy by Estrogen Receptor Status (2004) 
 
Figure 50 compares the accuracy of each modeling technique by ER status for cases registered 
in 2004 which are tagged ‘Dead’ at the cut-off date. The status is recorded as – positive, 
negative, borderline and unknown. 52% of cases tagged ‘Dead’, at cut-off date, have positive 
ER status and 30% cases have negative ER status. The highest number of cases have positive 
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ER status, CHAID has the highest accuracy for such cases, i.e. 93% followed by Ensemble 
with 91% accuracy. C&RT has the lowest accuracy for such cases. However, C&RT has the 
highest accuracy for cases having negative ER status. Neural Network overall has low accuracy 
as compared to other modeling techniques. 
 
Figure 51. Accuracy by Progesterone Receptor Status (2004) 
 
 
Figure 51 compared the actual and measured average survival months by PR status for cases 
registered in 2004. The PR status is recorded as – positive, negative, borderline and unknown. 
42% of ‘Dead’ cases have negative PR status, and 38% of cases have a positive PR status. The 
graph shows exciting trends. C&RT has highest accuracy for cases with negative PR status and 
unknown PR status. However, CHAID has the highest accuracy for cases with positive PR 
status. On the other hand, Neural Network and Ensemble have second highest accuracy, i.e. 
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89% for cases with positive PR status. The Ensemble has the highest accuracy for cases with 
borderline PR status. 
 
4.2.2.6 Accuracy by Behavior Code ICD-O-3 
 
 
Figure 52. Accuracy by Behavior ICD-O-3 (2004) 
 
 
In Figure 52, the accuracy of modeling techniques is compared by behavior type for cases 
registered in 2004 which are tagged ‘Dead’ at the cut-off date. The cases are categorized as 
malignant (invasive) and carcinoma in situ (non-invasive).  The Ensemble has the highest 
accuracy of 91% followed by CHAID and C&RT respectively. However, Neural Network has 
the lowest accuracy for malignant cases. On the other hand, for the cases having carcinoma in 
situ behavior type, Neural Network has the highest accuracy. However, the Neural Network 
also highest accuracy for carcinomic cases (97%) followed by Ensemble, CHAID and C&RT 
respectively.  
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4.2.3 Impact of Retraining Breast Cancer Predictive Model  
 
Predictive model deployment is an iterative process. The data with which the prediction model 
is trained should have the same data distribution as the data on which it is tested [96]. With 
new technological improvements, early detection and screening techniques, the breast cancer 
data distribution has changed over time [97, 98]. To get more accurate results, retraining the 
existing model with new data is a good practice. Retraining the predictive model in IBM SPSS 
Modeler is possible. The existing model is trained with new data, reproducing/refreshing the 
modeling nuggets. The impact of retraining the model is presented in the next subsections. 
4.2.3.1 Case Study of Cases Diagnosed in 2008 
 
In the year 2008, a total of 67,017 breast cancer cases were registered in the SEER database. 
The predictive model is tested for cases registered in the year 2008 (which is outside training 
range). The vital status of actual and predicted model’s outcome (i.e. measured) are compared. 
 
Figure 53. Vital Status comparison (2008) 
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As shown in Figure 53, out of total cases diagnosed in 2008, 83.39% of cases are tagged 
‘Alive’ and 16.11% are tagged ‘Dead’ at the cut-off date. The predictive model also predicts 
83.39% of cases as ‘Alive’ and 16.11% as ‘Dead’ as of the cut-off date (December 31, 2013). 
This shows that the predictive model is predicting the exact number of mortalities for the year 
2008. To check the predictive model’s accuracy in predicting survival months, measured 
survival months are compared with actual survival months. The results are presented by 
average and accuracy. 
Further, the existing model is retrained with more recent data, i.e. cases diagnosed from 
2003 to 2007. The same testing dataset (of cases diagnosed in 2008) is used to test the measured 
average and accuracy of the retrained model. The results from both the experiments are 
compared by plotting actual vs measured survival months. As long as the model is trained with 
the recent data possible, it produces a more accurate outcome.  
 
4.2.3.1.1 Comparing outcomes of Predictive Model with Retrained Model by Average 
Survival Months 
 
Figure 54 compares the actual and measured average survival months. A total of 6,774 cases 
are tagged ‘Dead’ at the cut-off date. The average survival months of ‘Dead’ cases is 28.37 
months. CHAID predicts 32 survival months followed by C&RT (39 months), Ensemble (42 
months) and Neural Network (53 months). This graph shows that the Neural Network, C&RT 
and Ensemble are not performing very well. 
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Figure 54. Average Survival Months Actual vs Measured (2008) 
 
 
Figure 55. Average Survival Months Actual vs Measured (2008) (Retrained model) 
 
 
On the other hand, when the predictive model is retrained with 2004-2007 data and 
tested with the same dataset (2008), the results change drastically. The measured survival 
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months of retrained model ranges from 28.09 to 28.51 survival months when the actual survival 
months is 28.37 (Figure 55). This shows the impact of retraining the model with the prediction 
outcomes improving exceptionally. 
 
4.2.3.1.2 Comparing outcomes of Predictive Model with Retrained Model by Accuracy  
 
Figure 56 compares the accuracy of the predictive model when trained with 1988-2003 data. 
Only cases tagged ‘Dead’ at the cut-off date are taken into consideration. The graph shows the 
CHAID has the highest accuracy, i.e. 86%, and C&RT and Ensemble technique’s accuracy is 
comparatively lower, i.e. 61% and 53%, respectively. Neural Network has the lowest accuracy 
i.e. 14%. When the model is retrained with 2004-2007 historical data, the accuracy improves 
drastically. 
 
 
Figure 56. Accuracy of Predictive Model (2008) 
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Figure 57. Accuracy of Retrained Predictive Model (2008) 
 
Figure 57 shows Ensemble has 100% accuracy, C&RT and Neural Network have 99% 
accuracy followed by CHAID. The summary of the impact of retraining the model is presented 
in Table 10. The ‘Trained’ columns represent results generated from 1988-2003 trained 
predictive model, and ‘Retrained’ columns represent the results generated by the retrained 
model (2004-2007). 
Actual Survival Months 
28.37 
Average Survival Months Accuracy 
Trained Retrained Trained Retrained 
Ensemble 42 28.51 53 100 
CHAID 32 28.11 86 97 
C&RT 39 29.33 61 99 
Neural 53 28.09 14 99 
 
Table 10. Impact of Retraining  
 
Apart from 2004 and 2008 test datasets as shown in above subsections, similar 
experiments were conducted for other datasets which are outside the training range, and similar 
results are achieved. 
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4.2.4 Summary of Predictive Modeling 
 
The developed predictive model is tested with different datasets outside the training data. 
Predicted average survival months and accuracy of each modeling technique is observed for 
cases diagnosed in 2004 and 2008. The test results are validated by comparing the actual 
survival months of cases tagged ‘Dead’ on the cut-off date. Following key observations are 
made: 
 The Ensemble of selected modeling techniques performs better than other models with 
93% accuracy.  
 CHAID with 92% accuracy ranks second following Ensemble technique. 
 C&RT and Neural Network modeling techniques have 80% and 66% accuracy, 
respectively. 
 Results are consistent across various attributes (age, marital status, regional nodes). 
 Ensemble and CHAID perform best amongst all other modeling techniques used in 
this study. 
 Neural Network performs poor consistently across all the experiments. Some 
exceptions were observed when the number of cases was low. 
 Testing the predictive model with 2008 dataset gives low accuracies for all the models 
 On retraining the predictive model with more recent data, the accuracy of the predictive 
model improved significantly resulting in Ensemble performing best with 100% 
accuracy. 
 The accuracy of Neural Networks improves upon retraining. The inconsistency of data, 
i.e. missing values of T, N and M variables in testing and training datasets does not 
exist anymore. The 2004-2007 retraining dataset has over 200,000 cases. The Neural 
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Networks is retrained with missing values of these variables and thus predicts with 
very high accuracy. 
All experimental results presented are for cases tagged “Dead” at the study cut-off date 
due to uncertainty of survival months beyond this date. The noted survival months of “Alive” 
cases is not their survival months as patients could have died one month, one year or 5 years 
beyond the study cut-off date. It is not possible to validate the results of “Alive” cases and 
hence they are not included in the results. However, if both “Alive” and “Dead” cases are taken 
into consideration, Neural Networks also perform well with higher accuracy across all the 
experiments. 
On testing with various other datasets outside training ranges, similar patterns of results 
are observed. By analysis of various data sets, it is concluded that the developed predictive 
model is a powerful application when retrained periodically. 
 
4.3 Summary  
 
In this chapter, the experimental results and analysis of the predictive model’s outcome are 
presented. The results are presented by comparing actual and measured survival months and 
validated by computing accuracy of each modeling technique. The visualization dashboard 
snapshots are also presented along with an analysis of each report.  In the next chapter, the 
conclusion of the thesis is presented along with the possible future work. 
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5. Conclusion and Future Work  
 
Breast cancer is the most common cancer in women across the globe. With an increasing 
number of breast cancer incidences an early detection and treatment is the ideal way to decrease 
breast cancer mortalities. It is also important to note that not all breast cancer patients die due 
to breast cancer, many deaths happen due to other diseases which are a consequence of breast 
cancer and metastasized cancers. Breast cancer remains the second most common cause of 
death in women after heart diseases. Despite technological advancements and early cancer 
detection techniques, one-size-fits-all is a common practice used for developing a cancer 
treatment. Data-driven research outcomes are steps towards advancements in cancer treatment. 
These outcomes include cancer prognosis, survival outcome and side effects of therapies. This 
research focuses on the survival outcome of breast cancer patient and uses historical data to 
develop a visualization dashboard and a predictive model. The survival outcome of the patient 
not only helps physicians in designing a custom treatment plan for each patient, but it also 
helps keeps the patient informed and involved in the process of cancer treatment.  
 
In this research, an interactive, end-to-end process to cleanse, integrate, analyze, and 
visualize enormous amount of data has been presented. The purpose is to enable healthcare 
professionals, patients and policymakers with a better understanding of the hidden patterns in 
data, which in turn, could be useful to collectively improve the quality of healthcare. Forty 
years of breast cancer data (over one million records) extracted from the SEER database was 
used to demonstrate the analytical power of data visualization. The research approach involved 
using several data preprocessing techniques on the raw data followed by a selection of the 
relevant variables, before feeding the processed data to the SQL Server for analysis. Tableau 
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was used for understanding and interpreting the data along several dimensions. Dynamic 
reports generated using the drill-down capabilities of the dashboard provide insights at a finer 
granularity. The dashboard shows incidence and mortality trends and highlights the underlying 
patterns observed in breast cancer patients which could be used to support clinical decisions 
made by physicians in formulating treatment plans. The dashboard is scalable and capable of 
integrating new data in real-time. Although SEER data from the US currently power the 
dashboard, it can be configured to use data from other sources as well. A better understanding 
of the incidence and mortality trends could potentially guide data-driven resource allocation. 
Physicians could also use this information to educate patients and create more awareness about 
the disease. 
The pre-processed data is used to develop a predictive model to predict survival months 
of individual breast cancer patient. For predictions, Neural Network, CHAID, C&RT modeling 
techniques along with their Ensemble are used, which predict survival months of each patient. 
The predictive model calculator allows user to enter values of variables such as Marital Status; 
Race/ethnicity; Age; Laterality; Histologic Type; Behavior Code; Regional nodes positive and 
examined; Cancer-directed surgery; Radiation; Surgery of Primary Site; ER and PR status; 
T, N, M value; Year of diagnosis. The predictive model is then run and produces survival 
months predicted by each modeling technique and the Ensemble modeling technique. The 
predictive model is developed in SPSS Modeler 18.1 [88] (explained in Chapter 3). 
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5.1 Future Work 
 
This research can be extended in several ways as described below: 
 
 The predictive model can be deployed on cloud and re-trained and tested online.  
 The calculator can be developed with a web-interface and hosted on available web services 
such as Amazon Web Services, IBM Bluemix. 
 A similar predictive model can be developed for other cancer types and diseases. 
 The developed predictive model can be trained and tested with different demographics data. 
 Automating the process of re-training the developed predictive model with the most recent 
data. 
 The Visualization dashboard can be extended to other diseases and cancer types. 
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Appendix B 
 
The list of all the variables selected with their definition9and coding are listed below: 
 
1) CS mets at DX-bone (2010+) 
“Identifies the presence of distant metastatic involvement of bone at time of diagnosis. The 
presence of metastatic bone disease at diagnosis is an independent prognostic indicator, and it 
is used by Collaborative Staging to derive TNM-M codes and SEER Summary Stage codes for 
some sites. This field should be coded for all solid tumors, Kaposi sarcoma, Unknown Primary 
Site, and Other and Ill-Defined Sites. Only available for 2010+ diagnosis. This includes only 
the bone, not the marrow.”  
 
Codes 
0: No 
1: Yes 
8: N/A 
9: Unknown 
14: Blank(s) 
 
 
2) CS mets at DX-lung (2010+) 
“Identifies the presence of distant metastatic involvement of the lung at the time of diagnosis. 
The presence of metastatic lung disease at diagnosis is an independent prognostic indicator, 
and it is used by collaborative Staging to derive TNM-M codes and SEER Summary Stage 
codes for some sites. Only available for 2010+ diagnosis.  Note: This includes only the lung, 
not pleura or pleural fluid.”  
 
Codes 
0: No 
1: Yes 
8: N/A 
9: Unknown 
14: Blank(s) 
 
 
 
 
 
                                                 
9 All the definitions are from SEER’s documentation for text files [49]. 
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3) CS mets at DX-liver (2010+) 
“Identifies the presence of distant metastatic involvement of the liver at time of diagnosis. The 
presence of metastatic liver disease at diagnosis is an independent prognostic indicator, and it 
is used by Collaborative Staging derive TNM-M codes and SEER Summary Stage codes for 
some sites. Only available for 2010+ diagnosis.”  
 
Codes 
0: No 
1: Yes 
8: N/A 
9: Unknown 
14: Blank(s) 
 
 
4) CS mets at DX-brain (2010+) 
“Identifies the presence of distant metastatic involvement of the brain at the time of diagnosis. 
The presence of metastatic brain disease at diagnosis is an independent prognostic indicator, 
and it is used by Collaborative Staging to derive TNM-M codes and SEER Summary Stage 
codes for some sites. This field should be coded for all solid tumors, Kaposi sarcoma, Unknown 
Primary Site, and Other and Ill-Defined Primary Sites. Only available for 2010+ diagnosis.”  
 
Codes 
0: No 
1: Yes 
8: N/A 
9: Unknown 
14: Blank(s) 
 
 
5) Breast Subtype (2010+) 
“Created with combined information from ER Status Recode Breast Cancer (1990+), PR Status 
Recode Breast Cancer (1990+), and Derived HER2 Recode (2010+).” 
 
Codes 
1: Her2+/HR+  
2: Her2+/HR-  
3: Her2-/HR+  
4: Triple Negative  
5: Unknown 
9: Not 2010+ Breast 
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6) Vital status recode (study cutoff used) 
“Any patient that dies after the follow-up cut-off date is recoded to alive as of the cut-off date.” 
 
Codes 
1: Alive 
4: Dead 
 
 
7) Age recode with < 1 year old 
“The age recode variable is based on Age at Diagnosis (single-year ages). The groupings used 
in the age recode variable are determined by the age groupings in the population data. This 
recode has 19 age groups in the age recode variable (< 1 year, 1-4 years, 5-9 years, 85+ years).” 
 
Codes 
00: Age 00 
01: Age 01-04 
02: Age 05-09 
03: Age 10-14 
04: Age 15-19 
05: Age 20-24 
06: Age 25-29 
07: Age 30-34 
08: Age 35-39 
09: Age 40-44 
10: Age 45-49 
11: Age 50-54 
12: Age 55-59 
13: Age 59-60 
14: Age 65-69 
15: Age 70-74 
16: Age 75-79 
17: Age 80-84 
18: Age 85+ 
99: Unknown Age 
 
 
8) Radiation 
“The method of radiation therapy performed as part of the first course of treatment.” 
 
Codes  
0: None; diagnosed at autopsy  
1: Beam radiation 
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2: Radioactive implants 
3: Radioisotopes 
4: Combination of 1 with 2 or 3  
5: Radiation, NOS – method or source not specified 
6: Other radiation (1973-1987 cases only) 
7: Patient or patient’s guardian refused radiation therapy 
8: Radiation recommended, unknown if administered 
9: Unknown if radiation administered 
 
9) Radiation sequence with surgery 
“The order in which surgery and radiation therapies were administered for those patients who 
had both surgery and radiation” 
 
Codes 
0: No radiation and/or surgery as defined above 
2: Radiation before surgery 
3: Radiation after surgery 
4: Radiation both before and after surgery 
5: Intraoperative radiation therapy 
6: Intraoperative radiation therapy with other radiation given before or after surgery 
9: Sequence unknown, but both surgery and radiation were given 
 
 
10)  N value-based on AJCC 3rd (1998-2003) 
“Derived by algorithm from extent of disease (EOD). N value denotes the degree of nearby 
lymph nodes involved.” 
 
Codes 
00: N0 
10: N1 
11: N1a 
12: N1b 
19: N1x 
20: N2 
21: N2a 
22: N2b 
23: N2c 
30: N3 
70: NXr 
80: Nxu 
90: NX 
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11)  M value-based on AJCC 3rd (1998-2003) 
“Derived by algorithm from extent of disease (EOD). M value denotes the presence of distant 
metastasis.” 
 
Codes 
00: M0 
10: M1 
99: MX 
11: M1a 
12: M1b 
 
 
12)  T value-based on AJCC 3rd (1998-2003) 
“Derived by algorithm from extent of disease (EOD). T value denotes the size of the original 
(primary) tumor.” 
 
Codes 
00: Tis 
01: Ta 
10: T1 
11: M1a 
12: M1b 
13: T1c 
16: T1a1 
17: T1a2 
19: T1x 
20: T2 
21: T2a 
22: T2b 
23: T2c 
29: T2x 
30: T3 
31: T3a 
32: T3b 
33: T3c 
39: T3x 
40: T4 
41: T4a 
42: T4b 
43: T4c 
44: T4d 
49: T4x 
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70: T0 
71: T0a 
72: T0b 
81: Txa 
82: TXb 
83: TXc 
84: TXd 
99: TX 
 
13)  Regional Nodes Positive 
“Records the exact number of regional lymph nodes examined by the pathologist that were 
found to contain metastases.” 
 
Codes 
0: All nodes examined are negative 
01-89: Exact number of nodes positive 
90: 90 or more nodes are positive 
95: Positive aspiration of lymph node(s) was performed 
97: Positive nodes are documented, but number is unspecified 
98: No nodes were examined 
99: Unknown whether nodes are positive; not applicable; not stated in patient record 
 
 
14)  Regional Nodes Examined 
“Records the total number of regional lymph nodes that were removed and examined by the 
pathologist.” 
 
Codes 
0: No nodes were examined 
01-89: Exact number of nodes examined 
90: 90 or more nodes were examined 
95: No regional nodes were removed, but aspiration of regional nodes was performed 
96: Regional lymph node removal was documented as a sampling, and the number of nodes 
is unknown/ not stated 
97: Regional lymph node removal was documented as a dissection, and the number of nodes 
is unknown/not stated 
98: Regional lymph node were surgically removed, but the number of lymph nodes is 
unknown/not stated and not documented as a sampling or dissection, nodes were 
examined, but the number is unknown 
99: Unknown whether nodes are positive; not applicable; not stated in patient record 
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15)  CS mets at dx (2004+) 
“Information on distant metastasis. Available for 2004+. Earlier cases may be converted and 
new codes added which weren't available for use prior to the current version of CS.” 
 
Codes 
0: No distant metastasis 
5: No clinical or radiographic evidence of distant metastasis, but deposits of molecularly 
or  microscopically  detected tumor cells in circulating blood, bone marrow or other non-
regional nodal tissue that are 0.2 millimeters (mm)  or less in a patient without symptoms or 
signs of metastasis 
7: Stated as M0(i+) with no other information on distant metastasis 
10: Distant lymph node(s): Cervical; NOS, Contralateral/bilateral axillary and/or internal 
mammary, Other than above. Distant lymph node(s), NOS 
40: Distant metastasis except distant lymph node(s) (code 10) Carcinomatosis 
42: Further contiguous extension: Skin over: Axilla, Contralateral (opposite) breast, 
Sternum, Upper abdomen. 
44: Metastasis: Adrenal (suprarenal) gland, Bone, other than adjacent rib, Contralateral 
(opposite) breast - if stated as metastatic Lung, Ovary, Satellite nodule(s) in skin other than 
primary breast 
50: (40 - 44) + 10 
60: Distant metastasis, NOS. Stated as M1 with no other information on distant metastasis 
99: Unknown; distant metastasis not stated. Distant metastasis cannot be assessed. Not 
documented in patient record. 
126: Unknown 
 
16)  CS tumor Size 
“Information on tumor size. Available for 2004+. Earlier cases may be converted and new 
codes added which weren't available for use prior to the current version of CS.” 
 
Codes 
0: Indicates no mass or no tumor found; for example, when a tumor of a stated primary 
site is not found, but the tumor has metastasized 
1-989: 1-989 millimeters 
990: Microscopic focus or foci only; no size of focus is given 
991: Described as less than 1 cm 
992: Described as less than 2 cm 
993: Described as less than 3 cm 
994: Described as less than 4 cm 
995: Described as less than 5 cm 
996: Site-specific codes where needed 
997: Site-specific codes where needed 
998: Site-specific codes where needed 
999: Unknown; size not stated; not stated in patient record 
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17)  CS Extension 
“Information on extension of the tumor. Available for 2004+. Earlier cases may be converted 
and new codes added which weren't available for use prior to the current version of CS.” 
 
Codes 
0: In situ: noninfiltrating; intraepithelial. Intraductal WITHOUT infiltration. Lobular 
neoplasia. 
50: Paget disease of nipple WITHOUT underlying tumor 
70: Paget Disease disease of nipple WITHOUT underlying invasive carcinoma 
pathologically 
100: Confined to breast tissue and fat including nipple and/or areola Localized, NOS 
110: Stated as T1mi with no other information on extension 
120: Stated as T1a with no other information on extension 
130: Stated as T1b with no other information on extension 
140: Stated as T1c with no other information on extension 
170: Stated as T1 (NOS) with no other information on extension or size 
180: Stated as T2 with no other information on extension or size 
190: Stated as T3 with no other information on extension or size 
200: Invasion of subcutaneous tissue. Local infiltration of dermal lymphatics adjacent to 
primary tumor involving skin by direct extension. Skin infiltration of primary breast including 
skin of nipple and/or areola. 
300: Attachment or fixation to pectoral muscle(s) or underlying tissue. Deep fixation. 
Invasion of (or fixation to) pectoral fascia or muscle 
380: OBSOLETE DATA CONVERTED V0203. See code 790. Stated as T4 (NOS) with no 
other information on extension 
390: OBSOLETE DATA CONVERTED V0203. See code 410. Stated as T4a with no other 
information on extension. 
400: Invasion of (or fixation to): Chest wall, Intercostal or serratus anterior muscle(s), 
Rib(s). See codes 610 (obsolete), 612-615, and 620 (obsolete) for combinations with this code. 
410: Stated as T4a with no other information on extension 
510: OBSOLETE DATA RETAINED V0200. Extensive skin involvement, including: 
Satellite nodule(s) in skin of primary breast, Ulceration of skin of breast. Any of the following 
conditions described as involving not more than 50% of the breast, or amount or percent  
512: Extensive skin involvement, including: Satellite nodule(s) in skin of primary breast, 
Ulceration of skin of breast. 
514: Any of the following conditions described as involving less than one-third (33%) of the 
breast WITHOUT a stated diagnosis of inflammatory carcinoma. WITH or WITHOUT 
dermal lymphatic infiltration: Edema of skin, En cuirasse, Erythema, Inflammation of skin, 
516: 514 + 512 
518: Any of the following conditions described as involving one third (33%) or more but 
less than or equal to half (50%) of the breast WITHOUT a stated diagnosis of inflammatory 
carcinoma.  WITH or WITHOUT dermal lymphatic infiltration: Edema of skin, En cuira 
519: 518 + 512 
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520: Any of the following conditions described as involving more than 50% of the breast 
WITHOUT a stated diagnosis of inflammatory carcinoma.  WITH or WITHOUT dermal 
lymphatic infiltration: Edema of skin, En cuirasse, Erythema, Inflammation of skin, Peau d'ora 
575: 520 + 512 
580: Any of the following conditions with amount or percent of breast involvement not 
stated and WITHOUT a stated diagnosis of inflammatory carcinoma.  WITH or WITHOUT 
dermal lymphatic infiltration: Edema of skin, En cuirasse, Erythema, Inflammation of skin, P 
585: 580 + 512 
590: OBSOLETE DATA CONVERTED V0203. See code 605. Stated as T4b with no other 
information on extension. 
600: Diagnosis of inflammatory carcinoma WITH a clinical description of inflammation, 
erythema, edema, peau d'orange, etc., involving less than one-third (33%) of the skin of the 
breast, WITH or WITHOUT dermal lymphatic infiltration. 
605: Stated as T4b with no other information on extension 
610: OBSOLETE DATA RETAINED V0200. (400) + (510) 
612: Any of (512-516) + 400 
613: Any of (518-519) + 400 
615: Any of (520-585) + 400 
620: OBSOLETE DATA RETAINED V0200. (400) + (520) 
680: Stated as T4c with no other information on extension 
710: OBSOLETE DATA RETAINED V0200. Diagnosis of inflammatory carcinoma WITH 
a clinical description of inflammation, erythema, edema, peau d'orange, etc., involving not 
more than 50% of the skin of the breast, WITH or WITHOUT dermal lymphatic infiltration. 
Infl 
715: OBSOLETE DATA RETAINED V0202. Diagnosis of inflammatory carcinoma WITH 
a clinical description of inflammation, erythema, edema, peau d'orange, etc., involving not 
more than one-third (33%) of the skin of the breast, WITH or WITHOUT dermal lymphatic 
infilt 
720: OBSOLETE DATA CONVERTED V0102. Description: Diagnosis of inflammatory 
carcinoma WITH a clinical diagnosis of inflammation, erythema, edema, peau d'orange, etc., 
of not more than 50% of the breast, WITH or WITHOUT dermal lymphatic infiltration. 
Inflammator 
725: Diagnosis of inflammatory carcinoma WITH a clinical description of inflammation, 
erythema, edema, peau d'orange, etc., involving one-third (33%) or more but less than or equal 
to one-half (50%) of the skin of the breast, WITH or WITHOUT dermal lymphatic i 
730: Diagnosis of inflammatory carcinoma WITH a clinical description of inflammation, 
erythema, edema, peau d'orange, etc., involving more than one-half (50%) of the skin of the 
breast, WITH or WITHOUT dermal lymphatic infiltration. 
750: Diagnosis of inflammatory carcinoma WITH a clinical description of inflammation, 
erythema, edema, peau d'orange, etc., but percent of involvement not stated, WITH or 
WITHOUT dermal lymphatic infiltration. Note: If percentage is known, code to 600, 725 
780: Stated as T4d with no other information on extension 
790: Stated as T4 (NOS) with no other information on extension 
950: No evidence of primary tumor 
999: Unknown; extension not stated. Primary tumor cannot be assessed. Not documented in 
patient record. 
1022: Unknown 
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18)  CS Lymph Nodes 
“Information on involvement of lymph nodes. Available for 2004+. Earlier cases may be 
converted and new codes added which weren't available for use prior to the current version of 
CS.” 
 
Codes 
0: No regional lymph node involvement OR isolated tumor cells (ITCs) detected by 
immunohistochemistry/immunohistochemical (IHC) methods or molecular methods ONLY. 
50: Evaluated pathologically: None; no regional lymph node involvement BUT ITCs 
detected on routine hematoxylin and eosin (H and E) stains. 
130: Evaluated pathologically: Axillary lymph node(s), ipsilateral, micrometastasis ONLY 
detected by IHC ONLY (At least one micrometastasis greater than 0.2 mm or more than 200 
cells AND all micrometastases less than or equal to 2 mm) 
150: Evaluated pathologically: Axillary lymph node(s), ipsilateral, micrometastasis ONLY 
detected or verified on H&E (At least one micrometastasis greater than 0.2 mm or more than 
200 cells AND all micrometastases less than or equal to 2 mm) Micrometastasis, NOS 
155: Evaluated pathologically: Stated as N1mi with no other information on regional lymph 
nodes 
250: Evaluated pathologically: Movable axillary lymph node(s), ipsilateral, positive with 
more than micrometastasis (At least one metastasis greater than 2 mm) 
255: Evaluated pathologically: Movable axillary lymph node(s), ipsilateral, positive with 
more than micrometastasis (At least one metastasis greater than 2 mm) 
257: Evaluated clinically: Clinically stated only as N1 (Clinical assessment because of 
neoadjuvant therapy or no pathology) 
258: Evaluated pathologically: Pathologically stated only as N1 [NOS], no information on 
which nodes were involved 
260: Stated as N1 [NOS] with no other information on regional lymph nodes 
280: OBSOLETE DATA RETAINED V0104. Stated as N2, NOS 
290: OBSOLETE DATA CONVERTED V0203. See code 610. Clinically stated only as N2, 
NOS (clinical assessment because of neoadjuvant therapy or no pathology) 
300: OBSOLETE DATA CONVERTED V0203. See code 620. Pathologically stated only 
as N2 NOS; no information on which nodes were involved 
500: OBSOLETE DATA RETAINED V0104. Fixed/matted ipsilateral axillary nodes, 
positive with more than micrometastasis (i.e., at least one metastasis greater than 2 mm). 
Fixed/matted ipsilateral axillary nodes, NOS 
510: Evaluated clinically: Fixed/matted ipsilateral axillary nodes clinically (Clinical 
assessment because of neoadjuvant therapy or no pathology). Stated clinically as N2a 
(Clinical assessment because of neoadjuvant therapy or no pathology) 
520: Evaluated pathologically: Fixed/matted ipsilateral axillary nodes clinically with 
pathologic involvement of lymph nodes WITH at least one metastasis greater than 2 mm 
600: Axillary/regional lymph node(s), NOS Lymph nodes, NOS 
610: Evaluated clinically: Clinically stated only as N2 [NOS] (Clinical assessment because 
of neoadjuvant therapy or no pathology)  
620: Evaluated pathologically: Pathologically stated only as N2 [NOS]; no information on 
which nodes were involved 
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630: Stated as N2 [NOS] with no other information on regional lymph nodes 
710: Evaluated pathologically: Internal mammary node(s), ipsilateral, positive on sentinel 
nodes but not clinically apparent (No positive imaging or clinical exam)  
WITHOUT axillary lymph node(s), ipsilateral 
720: Evaluated pathologically: Internal mammary node(s), ipsilateral, positive on sentinel 
nodes but not clinically apparent (No positive imaging or clinical exam) WITH axillary lymph 
node(s), ipsilateral 
730: Evaluated pathologically: Internal mammary node(s), ipsilateral, positive on sentinel 
nodes but not clinically apparent (No positive imaging or clinical exam) UNKNOWN if 
positive axillary lymph node(s), ipsilateral 
735: Evaluated clinically: Internal mammary node(s), ipsilateral, positive on sentinel nodes 
but primary not resected WITHOUT axillary lymph node(s), ipsilateral OR UNKNOWN if 
positive axillary lymph node(s) 
740: Internal mammary node(s), ipsilateral, clinically apparent (On imaging or clinical 
exam) WITHOUT axillary lymph node(s), ipsilateral 
745: Internal mammary node(s), ipsilateral, clinically apparent (On imaging or clinical 
exam) UNKNOWN if positive axillary lymph node(s), ipsilateral 
748: Stated as N2b with no other information on regional lymph nodes 
750: Infraclavicular lymph node(s) (subclavicular) (level III axillary nodes) (apical), 
ipsilateral WITH or WITHOUT axillary nodes(s) 
WITHOUT internal mammary node(s)  
755: Stated as N3a with no other information on regional lymph nodes 
760: OBSOLETE DATA RETAINED AND REVIEWED V0203. See codes 763 and765. 
Internal mammary node(s), ipsilateral, clinically apparent (on imaging or clinical exam) 
WITH axillary lymph node(s), ipsilateral, codes 150 to 600 WITH or WITHOUT 
infraclavicular (level III axillary nodes) (apical) lymph nodes. 
763: Internal mammary node(s), ipsilateral, clinically apparent (On imaging or clinical 
exam) WITH axillary lymph node(s), ipsilateral, codes 150 to 600 WITHOUT infraclavicular 
(level III axillary nodes) (apical) lymph nodes or unknown if infraclavicular (level III axillary 
nodes) (apical) lymph nodes involved 
764: Internal mammary node(s), ipsilateral, clinically apparent (On imaging or clinical 
exam) WITHOUT axillary lymph node(s), ipsilateral WITH infraclavicular (level III axillary 
nodes) (apical) lymph nodes involved 
765: Internal mammary node(s), ipsilateral, clinically apparent (On imaging or clinical 
exam) WITH axillary lymph node(s), ipsilateral. WITH infraclavicular (level III axillary 
nodes) (apical) lymph nodes involved 
768: Stated as N3b with no other information on regional lymph nodes 
770: OBSOLETE DATA RETAINED V0200. Internal mammary node(s), ipsilateral, 
clinically apparent (on imaging or clinical exam). UNKNOWN if positive axillary lymph 
node(s), ipsilateral 
780: OBSOLETE DATA RETAINED V0200. (750) + (770) 
790: OBSOLETE DATA CONVERTED V0203. See code 820. Stated as N3, NOS 
800: Supraclavicular node(s), ipsilateral 
805: Stated as N3c with no other information on regional lymph nodes 
810: Evaluated clinically: Clinically stated only as N3 [NOS] (Clinical assessment because 
of neoadjuvant therapy or no pathology) 
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815: Evaluated pathologically: Pathologically stated only as N3 [NOS]; no information on 
which nodes were involved 
820: Stated as N3, NOS with no other information on regional lymph nodes 
999: Unknown; regional lymph nodes not stated. Regional lymph node(s) cannot be 
assessed. Not documented in patient record 
1022: Unknown 
 
 
19) Marital Status at diagnosis 
“This variable identifies the patient’s marital status at the time of diagnosis for the reportable 
tumor.” 
 
Codes 
1: Single (never married) 
2: Married (including common law)  
3: Separated 
4: Divorced 
5: Widowed 
6: Unmarried or domestic partner (same sex or opposite sex or unregistered) 
9: Unknown 
 
 
20) ER Status Recode Breast Cancer (1990+) 
“Created by combining information from Tumor marker 1 (1990-2003), with information from 
CS site-specific factor 1 (2004+).” 
 
Codes 
1: Positive  
2: Negative  
3: Borderline  
4: Unknown  
9: Not 1990+ Breast 
 
 
21) PR Status Recode Breast Cancer (1990+) 
“Created by combining information from Tumor marker 2 (1990-2003), with information from 
CS site-specific factor 2 (2004+). This field is blank for non-breast cases and cases diagnosed 
before 1990.” 
 
Codes 
1: Positive  
2: Negative  
3: Borderline  
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4: Unknown  
9: Not 1990+ Breast 
 
 
22) SEER cause-specific death classification  
“This variable designates that the person died of their cancer for cause-specific survival.” 
 
Codes 
0: Alive or dead of other cause (Filtered out from the extracted dataset used in this research) 
1: Dead 
9: N/A not first tumor 
 
 
23) Survival Months 
“Created using complete dates, including days, therefore may differ from survival time 
calculated from year and month only” 
 
 
24)  Laterality 
“Laterality describes the side of a paired organ or side of the body on which the reportable 
tumor originated. Starting with cases diagnosed January 1, 2004 and later, laterality is coded 
for select invasive, benign, and borderline primary intracranial and CNS tumors.” 
 
Codes 
0: Not a paired site  
1: Right: origin of primary  
2:  Left: origin of primary  
3:  Only one side involved, right or left origin unspecified  
4: Bilateral involvement, lateral origin unknown; stated to be single primary- Both ovaries 
involved simultaneously, single histology,   Bilateral retinoblastomas,Bilateral Wilms’s 
tumors  
5: Paired site: midline tumor  
9: Paired site, but no information concerning laterality; midline tumor 
 
 
25)  Histologic Type ICD-O-3 
“Histologic Type describes the microscopic composition of cells and/or tissue for a specific 
primary. The tumor type or histology is a basis for staging and determination of treatment 
options. It affects the prognosis and course of the disease. The International Classification of 
Diseases for Oncology, Third Edition (ICD-O-3) is the standard reference for coding the 
histology for tumors diagnosed in 2001 and later. All ICD-O-2 histologies for 1973-2000 were 
converted to ICD-O-3.” 
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Codes 
0:  Benign (Reportable for intracranial and CNS sites only)  
1:  Uncertain whether benign or malignant, borderline malignancy, low malignant potential, 
and uncertain malignant potential (Reportable for intracranial and CNS sites only)  
2: Carcinoma in situ; intraepithelial; noninfiltrating; noninvasive 
3: Malignant, primary site (invasive) 
 
 
26)  Race/ethnicity 
“Recode which gives priority to non-white races for persons of mixed races.” 
 
Codes 
01: White  
02: Black 
03: American Indian, Aleutian, Alaskan Native or Eskimo (includes all indigenous 
populations of the Western hemisphere)   
04: Chinese  
05: Japanese 
06: Filipino 
07: Hawaiian 
08: Korean (Effective with 1/1/1988 dx) 
10: Vietnamese (Effective with 1/1/1988 dx) 
11: Laotian (Effective with 1/1/1988 dx) 
12: Hmong (Effective with 1/1/1988 dx) 
13: Kampuchean (including Khmer and Cambodian) (Effective with 1/1/1988 dx) 
14: Thai (Effective with 1/1/1994 dx) 
15: Asian Indian or Pakistani, NOS (Effective with 1/1/1988 dx) 
16: Asian Indian (Effective with 1/1/2010 dx) 
17: Pakistani (Effective with 1/1/2010 dx) 
20: Micronesian, NOS (Effective with 1/1/1991) 
21: Chamorran (Effective with 1/1/1991 dx) 
22: Guamanian, NOS (Effective with 1/1/1991 dx) 
25: Polynesian, NOS (Effective with 1/1/1991 dx) 
26: Tahitian (Effective with 1/1/1991 dx) 
27: Samoan (Effective with 1/1/1991 dx) 
28: Tongan (Effective with 1/1/1991 dx)   
30: Melanesian, NOS (Effective with 1/1/1991 dx) 
31: Fiji Islander (Effective with 1/1/1991 dx) 
32: New Guinean (Effective with 1/1/1991 dx) 
96: Other Asian, including Asian, NOS and Oriental, NOS (Effective with 1/1/1991 dx) 
97: Pacific Islander, NOS (Effective with 1/1/1991 dx) 
98: Other 
99: Unknown 
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27)  Year of Diagnosis 
“The year of diagnosis is the year the tumor was first diagnosed by a recognized medical 
practitioner, whether clinically or microscopically confirmed.” 
 
 
28)  Behavior Code ICD-O3 
“SEER requires registries to collect malignancies with in situ /2 and malignant /3 behavior 
codes as described in ICD-O-3. SEER requires registries to collect benign /0 and borderline /1 
intracranial and CNS tumors for cases diagnosed on or after 1/1/2004. Behavior is the fifth 
digit of the morphology code after the slash (/).” 
 
Codes 
0: Benign (Reportable for intracranial and CNS sites only)  
1: Uncertain whether benign or malignant, borderline malignancy, low malignant potential, 
and uncertain malignant potential (Reportable for intracranial and CNS sites only)  
2: Carcinoma in situ; intraepithelial; noninfiltrating; noninvasive 
3: Malignant, primary site (invasive) 
 
 
29) Surgery of Primary Site 
“Surgery of Primary Site describes a surgical procedure that removes and/or destroys tissue of 
the primary site performed as part of the initial work-up or first course of therapy.” 
 
Codes 
00: None; no surgical procedure of primary site; diagnosed at autopsy only  
10-19: Site-specific codes. Tumor destruction; no pathologic specimen or unknown whether 
there is a pathologic specimen 
20-80: Site-specific codes. Resection; pathologic specimen 
90: Surgery, NOS. A surgical procedure to the primary site was done, but no information on 
the type of surgical procedure is provided.  
98: Special codes for hematopoietic, reticuloendothelial, immunoproliferative, 
myeloproliferative diseases; illdefined sites; and unknown primaries, except death certificate 
only 
99: Unknown if surgery performed; death certificate only 
 
 
30) Reason no cancer-directed surgery 
“This variable documents the reason that surgery was not performed on the primary site” 
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Codes 
0: Surgery performed 
1*: Surgery not recommended 
2*: Contraindicated due to other conditions (1973-2002) 
5: Patient died before recommended surgery 
6: Unknown reason for no surgery  
7* Patient or patient's guardian refused 
8: Recommended, unknown if done  
9: Unknown if surgery performed; Death Certificate Only case; Autopsy only case (2003+)  
*Codes not used prior to 1988.  Code ‘2’ used only for Autopsy only cases prior to 1988 
 
